10-K/A

0000950170-24-034266.txt : 20240320 0000950170-24-034266.hdr.sgml : 20240320 20240320171017 ACCESSION NUMBER: 0000950170-24-034266 CONFORMED SUBMISSION TYPE: 10-K/A PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240320 DATE AS OF CHANGE: 20240320 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Corbus Pharmaceuticals Holdings, Inc. CENTRAL INDEX KEY: 0001595097 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 464348039 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-37348 FILM NUMBER: 24768533 BUSINESS ADDRESS: STREET 1: 500 RIVER RIDGE DRIVE CITY: NORWOOD STATE: MA ZIP: 02062 BUSINESS PHONE: 617-963-0103 MAIL ADDRESS: STREET 1: 500 RIVER RIDGE DRIVE CITY: NORWOOD STATE: MA ZIP: 02062 FORMER COMPANY: FORMER CONFORMED NAME: SAV Acquisition Corp DATE OF NAME CHANGE: 20131220 10-K/A 1 crbp-20231231.htm 10-K/A 10-K/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K/A

(Amendment No. 1)

(Mark One)


☒	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2023


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ____________ TO ____________ .

Commission File Number 001-37348

Corbus Pharmaceuticals Holdings, Inc.

(Exact name of Registrant as specified in its Charter)


Delaware	46-4348039
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
500 River Ridge Drive Norwood, Massachusetts	02062
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (617) 963-0100

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	CRBP	The Nasdaq Capital Market

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer ☐		Accelerated filer ☐
Non-accelerated filer ☒		Smaller reporting company ☒
		Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

As of June 30, 2023, the last business day of the registrant’s most recently completed second fiscal quarter, the aggregate market value of the common stock held by non-affiliates of the registrant was approximately $34,571,068, based on the closing price of the registrant’s common stock on June 30, 2023.

As of March 8, 2024, the number of shares outstanding of the registrant’s common stock, $0.0001 par value per share, was 10,493,108.

Documents incorporated by reference

None.

EXPLANATORY NOTE

Corbus Pharmaceuticals Holdings, Inc. (the “Company”) is filing this Amendment No. 1 (this “Amendment No. 1”) to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Original Form 10-K”), filed with the Securities and Exchange Commission (the “SEC”) on March 12, 2024, only for the purpose of amending and restating Item 11 of Part III of the Original Form 10-K to include certain information which was inadvertently omitted in the Original Form 10-K.

In addition, pursuant to SEC rules, Item 15 of Part IV of the Original Form 10-K is hereby amended solely to include, as Exhibits 31.1 and 31.2, new certifications of our principal executive officer and principal financial officer pursuant to Rule 13a-14(a) under the Exchange Act of 1934 (the “Exchange Act”). Because no financial statements are included in this Amendment No. 1 and this Amendment No. 1 does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4, and 5 of such certifications have been omitted. We are not including new certifications required by Rule 13a-14(b) under the Exchange Act as no financial statements are included in this Amendment No. 1.

Except for the changes to Item 11 of Part III and the filing of related certifications added to the list of Exhibits in Item 15 of Part IV, this Amendment No. 1 makes no changes to the Original Form 10-K.

In addition, no other information has been updated for any subsequent events occurring after March 12, 2024, the date of the filing of the Original Form 10-K. Accordingly, this Amendment No. 1 should be read in conjunction with the Original Form 10-K and our other filings made with the SEC subsequent to the filing of the Original Form 10-K. Unless the context otherwise requires, references in this Amendment No. 1 to “Corbus,” the “Company,” “we,” “us,” or “our” mean Corbus Pharmaceuticals Holdings, Inc. and its subsidiaries unless we state otherwise, or the context otherwise indicates.

TABLE OF CONTENTS


ITEM		Page
	PART III
11.	Executive Compensation	1

	PART IV
15.	Exhibits and Financial Statement Schedules	8

PART III

Item 11. EXECUTIVE COMPENSATION

Executive Compensation

Our named executive officers for the year ended December 31, 2023 were Yuval Cohen, Ph.D., Director and Chief Executive Officer; Sean Moran, CPA, Chief Financial Officer and Rachael Brake, Ph.D. former Chief Scientific Officer.

Summary Compensation Table

The following table presents information regarding the total compensation awarded to, earned by, or paid to our chief executive officer and the two most highly-compensated executive officers (other than the chief executive officer) who were serving as executive officers as of December 31, 2023 and December 31, 2022 for services rendered in all capacities to us for the year ended December 31, 2023 and December 31, 2022. These individuals are our named executive officers for 2023.


Name and Principal Position	Year	Salary ($)	Bonus ($)	Stock Awards ($)	Option Awards ($) (1)	Non-equity Incentive Plan Compensation ($)	All Other Compensation ($) (2)	Total ($)
Yuval Cohen	2023	$598,850	$283,855	$—	$229,842	$—	$25,075	$1,137,622
Chief Executive Officer	2022	$598,071	$277,728	$—	$552,172	$—	$14,870	$1,442,841

Sean Moran	2023	$444,971	$135,403	$—	$107,975	$—	$28,907	$717,256
Chief Financial Officer	2022	$427,933	$132,480	$—	$199,563	$—	$18,640	$778,616

Rachael Brake	2023	$453,980	$200,000	$—	$161,735	$—	$24,152	$839,867
Chief Scientific Officer	2022	$427,779	$108,986	$—	$211,573	$—	$15,457	$763,795


(1)	Amounts reflect the grant date fair value of option awards granted in 2023 and 2022 in accordance with Accounting Standards Codification Topic 718. For information regarding assumptions underlying the valuation of equity awards, see Note 3 to our Consolidated Financial Statements and the discussion under “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Policies and Estimates - Stock-Based Compensation” included in Item 7 of this Annual Report on Form 10-K for the fiscal year ended December 31, 2023. These amounts do not correspond to the actual value that may be received by the named executive officers if the stock options are exercised.

(2)	Includes the following amounts in respect to company matching contributions under our 401(k) plan, individual health savings accounts, company-paid premiums for group term life insurance, and company-paid internet allowance. The company-paid life insurance premiums reflect payments for group term life policies maintained for the benefit of all employees.


Name	Year	Company 401(k) Matching Contribution ($)	Company Health Savings Account Matching Contribution ($)	Company-Paid Group Term Life Insurance Premiums ($)	Company-Paid Internet Allowance ($)	Total All Other Compensation ($)
Yuval Cohen	2023	$19,290	$4,000	$810	$975	$25,075
	2022	$9,085	$4,000	$810	$975	$14,870

Sean Moran	2023	$17,074	$4,000	$6,858	$975	$28,907
	2022	$10,101	$4,000	$3,564	$975	$18,640

Rachael Brake	2023	$17,935	$4,000	$1,242	$975	$24,152
	2022	$9,240	$4,000	$1,242	$975	$15,457

Narrative Disclosure to Summary Compensation Table Employment Agreements

Yuval Cohen

We entered an employment agreement with Dr. Cohen which became effective April 11, 2020 (the “2020 Cohen Agreement”). The 2020 Cohen Agreement was effective for a period of two years. The 2020 Cohen Agreement provides for Dr. Cohen to serve as Chief Executive Officer and provides for an annual base salary of $559,000. In addition, pursuant to the 2020 Cohen Agreement, Dr. Cohen will be eligible to receive an annual bonus, which is targeted at up to 60% of his base salary but which may be adjusted by the Board based on his individual performance and the Company’s performance as a whole. Pursuant to the terms of the 2020 Cohen Agreement, Dr. Cohen will be eligible to receive, from time to time, equity awards under the Company’s existing equity incentive plan, or any other equity incentive plan the Company may adopt in the future, and the amounts of such awards, if any, will be determined by the Board or Compensation Committee, in their discretion. Dr. Cohen will be subject to non-compete provisions, which apply during the term of his employment and for a period of six months from the date of cessation of his employment, subject to the Company providing as severance ((x) if the Company terminates Dr. Cohen’s employment without cause or he terminates his employment for good reason during the term of the 2020 Cohen Agreement and (y) Dr. Cohen timely executes and does not revoke a general release, which will include a non-compete covenant, and complies with covenants) twelve months of his base salary, other than during the Change in Control Period (as defined below), in which case it will be increased to twenty-four (24) months. Dr. Cohen will be subject to non-solicitation provisions, which apply during the term of his employment and for a period of twelve months from the date of cessation of his employment. In addition, the 2020 Cohen Agreement contains customary confidentiality and assignment of inventions provisions. If the Company terminates Dr. Cohen’s employment without cause or he terminates his employment for good reason during the term of the 2020 Cohen Agreement, other than during the Change in Control Period, the Company will be required to provide as severance reimbursement of the cost of COBRA coverage (or to use commercially reasonable best efforts to provide the cost of other comparable coverage if COBRA reimbursement would incur tax penalties or violate the law) for twelve months, and he may be paid a pro-rated bonus, each subject to his timely execution and non-revocation of a general release, which will include a non-compete covenant, and continuing compliance with covenants. If the Company terminates Dr. Cohen’s employment without cause or he terminates his employment for good reason during the term of the 2020 Cohen Agreement, and within the three months immediately prior to a change in control or the twelve months immediately following a change in control (the “Change in Control Period”), the Company will be required to provide as severance reimbursement of the cost of COBRA coverage (or to use commercially reasonable best efforts to provide the cost of other comparable coverage if COBRA reimbursement would incur tax penalties or violate the law) for twenty-four (24) months, accelerated vesting of all of his outstanding options, restricted stock and other equity incentive awards and his current year bonus at two (2) times target levels, each subject to his timely execution and non-revocation of a general release which will include a non-compete covenant, and continuing compliance with covenants. Dr. Cohen’s severance payments and other applicable payments and benefits will be subject to reduction to the extent doing so would put him in a better after-tax position after taking into account any excise tax he may incur under Internal Revenue Code Section 4999 in connection with any change in control of us or his subsequent termination of employment. The 2020 Cohen Agreement expired on April 11, 2022.

Effective April 11, 2022, we entered into a fourth amended and restated employment agreement with Dr. Cohen, which is effective for a period of two years. Dr. Cohen’s employment agreement provides for him to serve as Chief Executive Officer and provides for an annual base salary of $598,850. In addition, Dr. Cohen is eligible to receive an annual bonus, which is targeted at up to 60% of his base salary but which may be adjusted by our Board based on his individual performance and our performance as a whole. Pursuant to the terms of the employment agreement, Dr. Cohen is eligible to receive, from time to time, equity awards under our existing equity incentive plan, or any other equity incentive plan we may adopt in the future, and the terms and conditions of such awards, if any, will be determined by our Board or Compensation Committee, in their discretion. Dr. Cohen is subject to non-compete provisions, which apply during the term of his employment and for a period of six months from the date of cessation of his employment, subject to the Company providing as severance ((x) if we terminate Dr. Cohen’s employment without cause or he terminates his employment for good reason during the term of his employment agreement and (y) Dr. Cohen timely executes and does not revoke a general release, which will include a non-compete covenant, and complies with such covenants) twelve months of his base salary, other than during the Change in Control Period (as defined below), in which case it will be increased to twenty-four (24) months. Dr. Cohen will be subject to non-solicitation provisions, which apply during the term of his employment and for a period of twelve months from the date of cessation of his employment. In addition, the employment agreement contains customary confidentiality and assignment of inventions provisions. If we terminate Dr. Cohen’s employment without cause or he terminates his employment for good reason during the term of his employment agreement, other than during the Change in Control Period, we are required to pay him as severance reimbursement of the cost of COBRA coverage (or to use commercially reasonable best efforts to provide the cost of other comparable coverage if COBRA reimbursement would incur tax penalties or violate the law) for twelve months, and he may be paid a pro-rated bonus, each subject to his timely execution of a general release, which will include a non-compete covenant, and continuing compliance with such covenants. If we terminate Dr. Cohen’s employment without cause or he terminates his employment for good reason during the term of the employment agreement, and within the three months immediately prior to a change in control or the twelve months immediately following a

change in control (the “Change in Control Period”), we are required to provide as severance reimbursement of the cost of COBRA coverage (or to use commercially reasonable best efforts to provide the cost of other comparable coverage if COBRA reimbursement would incur tax penalties or violate the law) for twenty-four (24) months, accelerated vesting of all of his outstanding options, restricted stock and other equity incentive awards and his current year bonus at two (2) times target levels, each subject to his timely execution and non-revocation of a general release which will include a non-compete covenant, and continuing compliance with such covenants. Dr. Cohen’s severance payments and other applicable payments and benefits will be subject to reduction to the extent doing so would put him in a better after-tax position after taking into account any excise tax he may incur under Internal Revenue Code Section 4999 in connection with any change in control of the Company or his subsequent termination of employment. Dr. Cohen’s employment agreement expires on April 11, 2024.

Sean Moran

We entered an employment agreement with Mr. Moran which became effective April 11, 2020 (the “2020 Moran Agreement”). The 2020 Moran Agreement was effective for a period of two years. The 2020 Moran Agreement provides for Mr. Moran to serve as Chief Financial Officer and provides for an annual base salary of $400,000. In addition, pursuant to the 2020 Moran Agreement, Mr. Moran will be eligible to receive an annual bonus, which is targeted at up to 40% of his base salary but which may be adjusted by the Board based on his individual performance and the Company’s performance as a whole. Pursuant to the terms of the 2020 Moran Agreement, Mr. Moran will be eligible to receive, from time to time, equity awards under the Company’s existing equity incentive plan, or any other equity incentive plan the Company may adopt in the future, and the payments of such awards, if any, will be determined by the Board or Compensation Committee, in their discretion. Mr. Moran is subject to non-compete provisions, which apply during the term of his employment and for a period of six months from the date of cessation of his employment, subject to the Company providing as severance ((x) if the Company terminates Mr. Moran’s employment without cause or he terminates his employment for good reason during the term of the 2020 Moran Agreement and (y) he timely executes and does not revoke a general release, which will include a non-compete covenant, and complies with covenants.) twelve months of his base salary, other than during the Change in Control Period (as defined below), in which case it will be increased to eighteen (18) months. Mr. Moran will be subject to non-solicitation provisions, which apply during the term of his employment and for a period of twelve months from the date of cessation of his employment. In addition, the 2020 Moran Agreement contains customary confidentiality and assignment of inventions provisions. If the Company terminates Mr. Moran’s employment without cause or he terminates his employment for good reason during the term of the 2020 Moran Agreement, other than during the Change in Control Period, the Company will be required to pay him as severance reimbursement of the cost of COBRA (or to use commercially reasonable best efforts to provide the cost of other comparable coverage if COBRA reimbursement would incur tax penalties or violate the law) for twelve months, and he may be paid a pro-rated bonus, each subject to his timely execution and non-revocation of a general release, which will include a non-compete covenant, and continuing compliance with covenants. If the Company terminates Mr. Moran’s employment without cause or he terminates his employment for good reason during the term of the 2020 Moran Agreement, and during the Change in Control Period, the Company will be required to pay him as severance reimbursement of the cost of COBRA coverage (or to use commercially reasonable best efforts to provide the cost of other comparable coverage if COBRA reimbursement would incur tax penalties or violate the law) for eighteen (18) months, accelerated vesting of all of his outstanding options, restricted stock and other equity incentive awards and his current year bonus at target levels, each subject to his timely execution and non-revocation of a general release, which will include a non-compete covenant, and continuing compliance with covenants. Mr. Moran’s severance payments and other applicable payments and benefits will be subject to reduction to the extent doing so would put him in a better after-tax position after taking into account any excise tax he may incur under Internal Revenue Code Section 4999 in connection with any change in control of the Company or his subsequent termination of employment. The 2020 Moran Agreement expired on April 11, 2022.

Effective April 11, 2022, we entered into a fifth amended and restated employment agreement with Mr. Moran, which is effective for a period of two years. Mr. Moran’s employment agreement provides for him to serve as Chief Financial Officer and provides for an annual base salary of $428,490. In addition, Mr. Moran is eligible to receive an annual bonus, which is targeted at up to 40% of his base salary but which may be adjusted by our Board based on his individual performance and our performance as a whole. Pursuant to the terms of the employment agreement, Mr. Moran is eligible to receive, from time to time, equity awards under our existing equity incentive plan, or any other equity incentive plan we may adopt in the future, and the terms and conditions of such awards, if any, will be determined by our Board or Compensation Committee, in their discretion. Mr. Moran is subject to non-compete provisions, which apply during the term of his employment and for a period of six months from the date of cessation of his employment, subject to the Company providing as severance ((x) if we terminate Mr. Moran’s employment without cause or he terminates his employment for good reason during the term of the employment agreement and (y) he timely executes and does not revoke a general release, which will include a non-compete covenant, and complies with such covenants) twelve months of his base salary, other than during the Change in Control Period, in which case it will be increased to eighteen (18) months. Mr. Moran will be subject to non-solicitation provisions, which apply during the term of his employment and for a period of twelve months from the date of cessation of his employment. In addition, the employment agreement contains customary confidentiality and assignment of inventions provisions. If we terminate Mr. Moran’s employment without cause or he terminates

his employment for good reason during the term of his employment agreement, other than during the Change in Control Period, we are required to pay him as severance reimbursement of the cost of COBRA coverage (or to use commercially reasonable best efforts to provide the cost of other comparable coverage if COBRA reimbursement would incur tax penalties or violate the law) for twelve months, and he may be paid a pro-rated bonus, each subject to his timely execution of a general release, which will include a non-compete covenant, and continuing compliance with such covenants. If we terminate Mr. Moran’s employment without cause or he terminates his employment for good reason during the term of the employment agreement, and during the Change in Control Period, we are required to pay him as severance reimbursement of the cost of COBRA coverage (or to use commercially reasonable best efforts to provide the cost of other comparable coverage if COBRA reimbursement would incur tax penalties or violate the law) for eighteen (18) months, accelerated vesting of all of his outstanding options, restricted stock and other equity incentive awards and his current year bonus at target levels, each subject to his timely execution and non-revocation of a general release, which will include a non-compete covenant, and continuing compliance with such covenants. Mr. Moran’s severance payments and other applicable payments and benefits will be subject to reduction to the extent doing so would put him in a better after-tax position after taking into account any excise tax he may incur under Internal Revenue Code Section 4999 in connection with any change in control of the Company or his subsequent termination of employment. Mr. Moran’s employment agreement expires on April 11, 2024.

Rachael Brake

On December 6, 2021, we entered an employment agreement with Dr. Brake (the “2021 Brake Agreement”). The 2021 Brake Agreement provides for her to serve, on an at-will basis, as Chief Scientific Officer and provides for an annual base salary of $410,000. In addition, Dr. Brake is eligible to receive an annual bonus, which is targeted at up to 40% of her base salary but may be adjusted by the Board based on her individual performance and the Company’s performance as a whole. Dr. Brake’s annual base salary and her targeted annual bonus could be adjusted annually by the Board. Pursuant to the terms of the 2021 Brake Agreement, Dr. Brake received an option to purchase up to 16,666 shares of the Company’s common stock pursuant to the Company’s 2014 Equity Compensation Plan, and is eligible, from time to time, to receive additional stock options or other awards (as permitted by the Plan), in amounts, if any, to be approved by the Board or the Compensation Committee in its discretion. Pursuant to the terms of the 2021 Brake Agreement, Dr. Brake is subject to non-compete and non-solicitation provisions, which apply during the term of her employment and for a period of six and twelve months, respectively, following termination of her employment. In addition, the 2021 Brake Agreement contains customary confidentiality and assignment of inventions provisions. Pursuant to the 2021 Brake Agreement, if the Company terminates Dr. Brake’s employment without cause or she terminates her employment for good reason during the term of the employment agreement, other than during the Change in Control Period, the Company may be required to pay her as severance twelve months of her base salary plus reimbursement of the cost of COBRA coverage (or to use commercially reasonable best efforts to provide the cost of other comparable coverage if COBRA reimbursement would incur tax penalties or violate the law) for twelve months, and she may be paid a pro-rated bonus, each subject to her timely execution and non-revocation of a general release and continuing compliance with covenants. If the Company terminates Dr. Brake’s employment without cause or she terminates her employment for good reason during the term of the employment agreement, and during the Change in Control Period, the Company may be required to pay her as severance eighteen (18) months of her base salary plus reimbursement of the cost of COBRA coverage (or to use commercially reasonable best efforts to provide the cost of other comparable coverage if COBRA reimbursement would incur tax penalties or violate the law) for eighteen (18) months, accelerated vesting of all of her outstanding options, restricted stock and other equity incentive awards and her current year bonus at target levels, each subject to her timely execution of a general release and continuing compliance with covenants. Dr. Brake’s severance payments and other applicable payments and benefits will be subject to reduction to the extent doing so would put her in a better after-tax position after taking into account any excise tax she may incur under Internal Revenue Code Section 4999 in connection with any change in control of the Company or her subsequent termination of employment. On February 2, 2024, Dr. Brake submitted a notice of resignation to the Company effective February 19, 2024.

Outstanding Equity Awards at Fiscal Year End

The following table summarizes, for each of the named executive officers, the number of shares of common stock underlying outstanding stock options held as of December 31, 2023.


	Equity Incentive Plan Awards
	Number of Securities Underlying Unexercised Options (#)				Number of Securities Underlying Unexercised Unearned		Option Exercise	Option Expiration
Name	Exercisable		Unexercisable		Options (#)		Price ($)	Date
Yuval Cohen	7,179	(1)	-	(1)	-		$4.97	1/28/2024
	9,091	(2)	-	(2)	-		$30.00	4/11/2024
	21,000	(3)	-	(3)	2,334	(3)	$30.00	10/22/2024
	17,667	(4)	-	(4)	-		$42.00	1/7/2026
	5,000	(5)	-	(5)	-		$261.30	10/6/2026
	12,583	(6)	-	(6)	-		$271.50	3/1/2027
	14,583	(7)	-	(7)	-		$250.50	1/4/2028
	18,833	(8)	-	(8)	-		$225.90	1/18/2029
	19,968	(9)	1,332	(9)	-		$135.90	3/6/2030
	45,166	(10)	18,600	(10)	-		$77.40	2/2/2031
	22,759	(12)	26,898	(12)	-		$14.10	2/1/2032
	-	(13)	66,318	(13)	-		$4.26	2/13/2033
Sean Moran	1,787	(2)	-	(2)	-		$30.00	4/11/2024
	3,525	(3)	-	(3)	392	(3)	$30.00	10/22/2024
	2,917	(4)	-	(4)	-		$42.00	1/7/2026
	2,500	(5)	-	(5)	-		$261.30	10/6/2026
	1,917	(6)	-	(6)	-		$271.50	3/1/2027
	2,917	(7)	-	(7)	-		$250.50	1/4/2028
	3,250	(8)	-	(8)	-		$225.90	1/18/2029
	3,531	(9)	236	(9)	-		$135.90	3/6/2030
	14,510	(10)	5,976	(10)	-		$77.40	2/2/2031
	8,225	(12)	9,722	(12)	-		$14.10	2/1/2032
	-	(13)	31,155	(13)	-		$4.26	2/13/2033
Rachael Brake	8,333	(11)	8,334	(11)	-		$22.50	12/6/2031
	8,720	(12)	10,307	(12)	-		$14.10	2/1/2032
	-	(13)	46,667	(13)	-		$4.26	2/13/2033


(1)	Represents options to purchase shares of our common stock granted on January 28, 2014. 25% of the option vested on January 28, 2015, and the remaining 75% of the option vested in equal monthly installments over a period of 36 months commencing on February 28, 2015.

(2)	Represents options to purchase shares of our common stock granted on April 11, 2014. 25% of the option vested on April 11, 2015, and the remaining 75% of the option vested in equal monthly installments over a period of 36 months commencing on May 11, 2015.

(3)	Represents options to purchase shares of our common stock granted on October 22, 2014. 12.5% of the option vested on October 22, 2015 and 37.5% of the option vested in equal monthly installments over a period of 36 months commencing on November 22, 2015. The remaining 50% of the option vested in tranches between 5% and 10% upon the achievement of eight individual business milestones.

(4)	Represents options to purchase shares of our common stock granted on January 7, 2016. 25% of these options vested on January 7, 2017 with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on February 7, 2017.

(5)	Represents options to purchase shares of our common stock granted on October 6, 2016. 25% of these options vested on October 6, 2017 with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on November 6, 2017.



(6)	Represents options to purchase shares of our common stock granted on March 1, 2017. 25% of these options vested on March 1, 2018 with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on April 1, 2018.

(7)	Represents options to purchase shares of our common stock granted on January 4, 2018. 25% of these options vest on January 4, 2019 with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on February 4, 2019.

(8)	Represents options to purchase shares of our common stock granted on January 18, 2019. 25% of these options vest on January 18, 2020 with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on February 18, 2020.

(9)	Represents options to purchase shares of our common stock granted on March 6, 2020. 25% of these options vest on March 6, 2021 and the remaining 75% of the option vested in equal monthly installments over a period of 36 months commencing on April 6, 2021.

(10)	Represents options to purchase shares of our common stock granted on February 2, 2021. 25% of these options vest on February 2, 2022 and the remaining 75% of the option vested in equal monthly installments over a period of 36 months commencing on March 2, 2022.

(11)	Represents options to purchase shares of our common stock granted on December 6, 2021. 25% of these options vest on December 6, 2022 and the remaining 75% of the option vested in equal monthly installments over a period of 36 months commencing on January 6, 2023.

(12)	Represents options to purchase shares of our common stock granted on February 1, 2022. 25% of these options vest on February 1, 2023 and the remaining 75% of the option vested in equal monthly installments over a period of 36 months commencing on March 1, 2023.

(13)	Represents options to purchase shares of our common stock granted on February 13, 2023. 25% of these options vest on February 13, 2024 and the remaining 75% of the option vested in equal monthly installments over a period of 36 months commencing on March 13, 2024.

Director Compensation Table

The following table sets forth information concerning the compensation paid to certain of our non-employee directors during 2023.


Name	Fees Earned or Paid in Cash ($)	Option Awards ($)(1)	Total ($)
Alan Holmer (2)	76,250	44,407	120,657
Avery Catlin (3)	67,500	44,407	111,907
Rachelle Jacques (4)	60,014	44,407	104,421
John Jenkins (5)	65,333	44,407	109,740
Peter Salzmann (6)	45,000	44,407	89,407
Anne Altmeyer (7)	46,104	44,407	90,511
Yong Ben (8)	37,440	56,766	94,206


(1)	Amounts reflect the aggregate grant date fair value of each stock option granted in 2023, in accordance with the Accounting Standards Codification Topic 718. These amounts do not correspond to the actual value that may be received by the directors if the stock options are exercised.

(2)	The aggregate number of shares of common stock underlying stock options outstanding as of December 31, 2023 held by Mr. Holmer was 21,073.

(3)	The aggregate number of shares of common stock underlying stock options outstanding as of December 31, 2023 held by Mr. Catlin was 20,444.

(4)	The aggregate number of shares of common stock underlying stock options outstanding as of December 31, 2023 held by Ms. Jacques was 16,560.

(5)	The aggregate number of shares of common stock underlying stock options outstanding as of December 31, 2023 held by Dr. Jenkins was 16,560.

(6)	The aggregate number of shares of common stock underlying stock options outstanding as of December 31, 2023 held by Dr. Salzmann was 15,403.

(7)	The aggregate number of shares of common stock underlying stock options outstanding as of December 31, 2023 held by Dr. Altmeyer was 10,607.

(8)	The aggregate number of shares of common stock underlying stock options outstanding as of December 31, 2023 held by Dr. Ben was 10,607.

Non-Employee Director Compensation Policy

Our Board has approved a director compensation policy for our non-employee directors. Other than reimbursement for reasonable expenses incurred in connection with attending Board and committee meetings, this policy provides for the following cash compensation effective May 2022:

•

each non-employee director is entitled to receive an annual fee from us of $40,000;

•

the chair of our Board will receive an annual fee from us of $30,000;

•

the chair of our audit committee will receive an annual fee from us of $20,000;

•

the chair of our compensation committee will receive an annual fee from us of $15,000;

•

the chair of our nominating and corporate governance committee will receive an annual fee from us of $10,000; and

•

each non-chairperson member of the audit committee, the compensation committee, and the nominating and corporate governance committee will receive annual fees from us of $10,000, $7,500, and $5,000, respectively.

Each non-employee director receives an annual equity award grant in an amount and on vesting terms, if applicable, to be determined annually by our Compensation Committee in consultation with an independent compensation consultant under our existing equity incentive plan, or any other equity incentive plan we may adopt in the future (the “Annual Non-Employee Director Grant”). Each non-employee director that joins our Board receives an initial grant to purchase that number of shares of our common stock under our existing equity incentive plan, or any other equity incentive plan we may adopt in the future, equal to two times the Annual Non-Employee Director Grant, which shall vest one year from the grant date, or other award with equivalent value and vesting terms to be determined by the Compensation Committee. Upon a change in control, as defined in our equity incentive plan, 100% of the shares underlying these options shall become vested and exercisable immediately prior to such change in control.

Scientific Advisory Board Compensation

We do not currently have a policy regarding compensation for our scientific advisory board members; however, each member of the scientific advisory board is eligible to receive a payment of $50,000 per year and an initial grant of 1,500 options to purchase shares of our common stock at the fair market value on the date of grant.

PART IV

Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

(a) List of Documents filed as part of this Report

(1) Consolidated Financial Statements

The financial statements and related notes, together with the report of EisnerAmper LLP (PCAOB ID: 274 and Location: Iselin, New Jersey) appear at pages F-2 through F-28 following the Exhibit List of the Original Form 10-K as required by Part II, Item 8 “Financial Statements and Supplementary Data”.

(2) Financial Statement Schedules.

Schedules are omitted because they are either not required, not applicable, or the information is otherwise included in the Original Form 10-K.

(3) Exhibits

The Company has filed with this report or incorporated by reference herein certain exhibits as specified below pursuant to Rule 12b-32 under the Exchange Act. See Exhibit Index following the signature page to this report for a complete list of documents filed with this report.


Exhibit No.		Description

3.1		Amended and Restated Certificate of Incorporation of the Company, as amended (incorporated herein by reference to Exhibit 3.1 of the Company’s Annual Report on Form 10-K filed with the SEC on March 7, 2023).

3.2		Amended and Restated Bylaws of the Company (incorporated herein by reference to Exhibit 3.2 of the Company’s Annual Report on Form 10-K filed with the SEC on March 7, 2023).

4.1		Form of Merger Warrant (incorporated by reference to Exhibit 4.1 of the Company’s Registration Statement on Form S-1 filed with the SEC on September 3, 2014).

4.2		Form of Replacement Warrant (incorporated by reference to Exhibit 4.2 of the Company’s Registration Statement on Form S-1 filed with the SEC on September 3, 2014).

4.3		Form of Investor Warrant (incorporated by reference to Exhibit 4.3 of the Company’s Registration Statement on Form S-1 filed with the SEC on September 3, 2014).

4.4		Form of Additional Replacement Warrant (incorporated by reference to Exhibit 4.4 of the Company’s Registration Statement on Form S-1 filed with the SEC on September 3, 2014).

4.5		Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.5 of the Company’s Registration Statement on Form S-1 filed with the SEC on September 3, 2014).

4.6		Registration Rights Agreement (incorporated by reference to Exhibit 4.6 of the Company’s Registration Statement on Form S-1 filed with the SEC on September 3, 2014).

4.7		Specimen Common Stock Certificate, $0.0001 par value (incorporated herein by reference to Exhibit 4.1 of the Company’s Registration Statement on Form S-3 filed with the SEC on November 10, 2015).

4.8		Warrant to Purchase Common Stock, dated as of January 26, 2018, issued to the Cystic Fibrosis Foundation (incorporated herein by reference to Exhibit 4.8 of the Company’s Annual Report on Form 10-K filed with the SEC on March 12, 2018).

4.9		Form of Warrant to Purchase Common Stock (incorporated herein by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K filed with the SEC on July 29, 2020).


4.10		Description of Capital Stock (incorporated herein by reference to Exhibit 4.10 of the Company’s Annual Report on Form 10-K filed with the SEC on March 7, 2023).


10.1		2014 Equity Compensation Plan (incorporated by reference to Exhibit 10.5 of the Company’s Registration Statement on Form S-1 filed with the SEC on September 3, 2014). †

10.2		Form of Incentive Stock Option Agreement (incorporated by reference to Exhibit 10.6 of the Company’s Registration Statement on Form S-1 filed with the SEC on September 3, 2014). †

10.3		Form of Non-Qualified Stock Option Agreement (incorporated by reference to Exhibit 10.7 of the Company’s Registration Statement on Form S-1 filed with the SEC on September 3, 2014). †

10.4		Form of Restricted Stock Agreement (incorporated by reference to Exhibit 10.8 of the Company’s Registration Statement on Form S-1 filed with the SEC on September 3, 2014). †

10.5		Form of Indemnification Agreement (incorporated by reference to Exhibit 10.15 of the Company’s Registration Statement on Amendment No. 1 to Form S-1 filed with the SEC on September 30, 2014). †

10.6		Award Agreement, dated April 9, 2015, between Cystic Fibrosis Foundation Therapeutics, Inc. and the Company (incorporated herein by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 13, 2015).#

10.7		Consulting Agreement, dated September 20, 2016, between Company and Orchestra Medical Ventures, LLC (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on September 21, 2016).

10.8		Lease, dated May 30, 2014, between Corbus Pharmaceuticals, Inc. and River Ridge Limited Partnership (incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K filed with the SEC on November 10, 2016).

10.9		First Amendment to Lease, dated August 27, 2015, between Corbus Pharmaceuticals, Inc. and River Ridge Limited Partnership (incorporated by reference to Exhibit 10.3 of the Company’s Current Report on Form 8-K filed with the SEC on November 10, 2016).

10.10		Second Amendment to Lease, dated March 30, 2016, between Corbus Pharmaceuticals, Inc. and River Ridge Limited Partnership (incorporated by reference to Exhibit 10.4 of the Company’s Current Report on Form 8-K filed with the SEC on November 10, 2016).

10.11		Third Amendment to Lease, dated September 13, 2016, between Corbus Pharmaceuticals, Inc. and River Ridge Limited Partnership (incorporated by reference to Exhibit 10.5 of the Company’s Current Report on Form 8-K filed with the SEC on November 10, 2016).

10.12		Lease Agreement, dated August 21, 2017, by and between Corbus Pharmaceuticals, Inc. and River Ridge Limited Partnership (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on August 22, 2017).

10.13		Guarantee, dated August 21, 2017, by Corbus Pharmaceuticals Holdings, Inc. (incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K filed with the SEC on August 22, 2017).


10.14		Cystic Fibrosis Program Related Investment Agreement, dated January 26, 2018, between Cystic Fibrosis Foundation Therapeutics, Inc. and the Company (incorporated herein by reference to Exhibit 10.33 of the Company’s Annual Report on Form 10-K filed with the SEC on March 12, 2018).#

10.15		License Agreement, dated as of September 20, 2018, between Corbus Pharmaceuticals, Inc. and Jenrin Discovery, LLC (incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 8, 2018).#


10.16		Lease Amendment No. 1, dated as of February 26, 2019, among River Ridge Limited Partnership, Corbus Pharmaceuticals, Inc. and Corbus Pharmaceuticals Holdings, Inc. (incorporated by reference to Exhibit 10.40 of the Company’s Annual Report on Form 10-K filed with the SEC on March 12, 2019).

10.17		Separation and General Release Agreement between Corbus Pharmaceuticals Holdings, Inc. and Mark Tepper, dated March 31, 2019 (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on April 1, 2019).

10.18		Lease Amendment No. 2, dated as of October 25, 2019, among River Ridge Limited Partnership, Corbus Pharmaceuticals, Inc. and Corbus Pharmaceuticals Holdings, Inc. (incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 7, 2019)

10.19		Loan and Security Agreement, dated as of July 28, 2020, by and between Corbus Pharmaceuticals Holdings, Inc., Corbus Pharmaceuticals, Inc., K2 HealthVentures LLC and Ankura Trust Company, LLC (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on July 29, 2020).

10.20		Separation and Release Agreement between the Company and Robert Discordia, dated November 30, 2020 (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on December 4, 2020).†

10.21		License Agreement between the Company and Milky Way BioPharma, LLC, dated May 25, 2021 (incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 12, 2021).#

10.22		License Agreement between the Company and The Regents of the University of California, dated May 26, 2021 (incorporated by reference to Exhibit 10.2 of the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 12, 2021).#

10.23		Separation and General Release Agreement between the Company and Barbara White, dated September 17, 2021 (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on September 22, 2021). †

10.24		Employment Agreement between the Company and Rachael Brake, effective as of December 6, 2021(incorporated herein by reference to Exhibit 10.31 of the Company’s Annual Report on Form 10-K filed with the SEC on March 8, 2022). †

10.25		Form of Fourth Amended and Restated Employment Agreement between Corbus Pharmaceuticals Holdings, Inc. and Yuval Cohen (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on April 15, 2022). †

10.26		Form of Fifth Amended and Restated Employment Agreement between Corbus Pharmaceuticals Holdings, Inc. and Sean Moran (incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K, filed with the SEC on April 15, 2022). †

10.27		Form of Second Amended and Restated Employment Agreement between Corbus Pharmaceuticals Holdings, Inc. and Craig Millian (incorporated by reference to Exhibit 10.3 of the Company’s Current Report on Form 8-K, filed with the SEC on April 15, 2022). †

10.28		Second Amendment to Loan and Security Agreement, dated as of July 28, 2020, by and between Corbus Pharmaceuticals Holdings, Inc., Corbus Pharmaceuticals, Inc., K2 HealthVentures LLC and Ankura Trust Company, LLC (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on October 31, 2022).

10.29		License Agreement between the Company and CSPC Megalith Biopharmaceutical Co., Ltd. (incorporated herein by reference to Exhibit 10.29 of the Company’s Annual Report on Form 10-K filed with the SEC on March 7, 2023).


10.30		Separation and General Release Agreement between the Company and Craig Millian, dated April 24, 2023 (incorporated herein by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on April 24, 2023). †

10.31		Open Market Sale Agreement, dated April 7, 2020, by and between the Registrant and Jefferies LLC (incorporated by reference to Exhibit 1.2 of the Company’s Registration Statement on Form S-3 filed with the SEC on April 7, 2020).

10.32		Amendment No. 1 to Open Market Sale Agreement, dated May 31, 2023, by and between the Registrant and Jefferies LLC (incorporated by reference to Exhibit 1.3 of the Company’s Registration Statement on Form S-3 filed with the SEC on June 1, 2023).

10.33		Form of Service Agreement between Corbus International Limited and Dominic Smethurst, dated February 27, 2024.*** †


21.1		List of Subsidiaries of the Company.***

23.1		Consent of EisnerAmper LLP.***

31.1		Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).*

31.2		Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).*

32.1		Certification of Chief Executive Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b).****

32.2		Certification of Chief Financial Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b).****

97.1		Compensation Recovery Policy.*** †

101.INS	Inline	Inline XBRL Instance Document.*** – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH	Inline	Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents

104		The cover page from the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, has been formatted in Inline XBRL***

* Filed herewith.

** Furnished, not filed.

*** Previously filed.

**** Previously furnished.

# Confidential treatment has been granted with respect to certain portions of this exhibit. Omitted portions have been submitted separately to the SEC.

† Indicates a management contract or compensation plan, contract or arrangement.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	CORBUS PHARMACEUTICALS HOLDINGS, INC.

Date: March 20, 2024	By:	/s/ Yuval Cohen
	Name:	Yuval Cohen
	Title:	Chief Executive Officer
		(Principal Executive Officer)

EX-31.1 2 crbp-ex31_1.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT

TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Yuval Cohen, certify that:


1.	I have reviewed this annual report on Form 10-K/A for the period ended December 31, 2023 of Corbus Pharmaceuticals Holdings, Inc.;


2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.	[Reserved.]

4.	[Reserved.]

    5.

    [Reserved.]

     
Date: March 20, 2024



	/s/ Yuval Cohen
	Yuval Cohen
	Chief Executive Officer
	(Principal Executive Officer)

EX-31.2 3 crbp-ex31_2.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT

TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Sean M. Moran, certify that:


1.	I have reviewed this annual report on Form 10-K/A for the period ended December 31, 2023 of Corbus Pharmaceuticals Holdings, Inc.;


2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.	[Reserved.]

4.	[Reserved.]


5.		[Reserved.]
	Date: March 20, 2024

	/s/ Sean Moran
	Sean Moran
	Chief Financial Officer
	(Principal Accounting and Financial Officer)

EX-101.SCH 4 crbp-20231231.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100020 - Disclosure - COMMITMENTS AND CONTINGENCIES - SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100030 - Disclosure - NOTES PAYABLE - SCHEDULE OF NOTES PAYABLE (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Consolidated Statements of Operations 2 link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 100070 - Statement - Consolidated Statement of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 100080 - Statement - Consolidated Statement of Stockholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100090 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - NATURE OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - LIQUIDITY link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - INVESTMENTS link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - LICENSE AGREEMENT link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - ACCRUED EXPENSES link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - DEVELOPMENT AWARDS AND DEFERRED REVENUE link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - PREFERRED STOCK link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - COMMON STOCK link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - STOCK BASED COMPENSATION AWARDS link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - WARRANTS link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - DERIVATIVE LIABILITY link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - INVESTMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - ACCRUED EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - DEVELOPMENT AWARDS AND DEFERRED REVENUE (Tables) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - STOCK BASED COMPENSATION AWARDS (Tables) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - WARRANTS (Tables) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - DERIVATIVE LIABILITY (Tables) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - LIQUIDITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF CASH AND CASH EQUIVALENTS (Details) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF COMPUTATION OF NET LOSS PER COMMON SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF NET LOSS PER COMMON SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - SUMMARY OF INVESTMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - INVESTMENTS - SUMMARIZES THE AMORTIZED COST AND FAIR VALUE (Details) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - SCHEDULE OF AVAILABLE FOR SALE DEBT SECURITIES BY CONTRACTUAL MATURITY (Details) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - INVESTMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS (Details) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - LICENSE AGREEMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - SUMMARY OF PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995895 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995905 - Disclosure - COMMITMENTS AND CONTINGENCIES - SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 995915 - Disclosure - COMMITMENTS AND CONTINGENCIES - SCHEDULE OF LEASE COSTS (Details) link:presentationLink link:calculationLink link:definitionLink 995925 - Disclosure - COMMITMENTS AND CONTINGENCIES - SUMMARY OF UNDISCOUNTED SUBLEASE CASH INFLOWS (Details) link:presentationLink link:calculationLink link:definitionLink 995935 - Disclosure - NOTES PAYABLE - SCHEDULE OF NOTES PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 995945 - Disclosure - NOTES PAYABLE - SCHEDULE OF PRINCIPAL MATURITIES ON LONG TERM DEBT (Details) link:presentationLink link:calculationLink link:definitionLink 995955 - Disclosure - NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995965 - Disclosure - SCHEDULE OF ACCRUED EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 995975 - Disclosure - DEVELOPMENT AWARDS AND DEFERRED REVENUE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995985 - Disclosure - DEVELOPMENT AWARDS AND DEFERRED REVENUE - SCHEDULE OF ROLL FORWARD OF DEFERRED REVENUE (Details) link:presentationLink link:calculationLink link:definitionLink 995995 - Disclosure - COMMON STOCK (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 996005 - Disclosure - SCHEDULE OF COMPONENTS OF NET DEFERRED TAX ASSET (Details) link:presentationLink link:calculationLink link:definitionLink 996015 - Disclosure - SCHEDULE OF COMPONENTS NET LOSS (Details) link:presentationLink link:calculationLink link:definitionLink 996025 - Disclosure - SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION - (Details) link:presentationLink link:calculationLink link:definitionLink 996035 - Disclosure - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 996045 - Disclosure - PREFERRED STOCK (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink 996055 - Disclosure - STOCK-BASED COMPENSATION AWARDS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 996065 - Disclosure - STOCK-BASED COMPENSATION AWARDS - SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details) link:presentationLink link:calculationLink link:definitionLink 996075 - Disclosure - STOCK-BASED COMPENSATION AWARDS - SUMMARY OF FAIR VALUE OF OPTIONS GRANTED (Details) link:presentationLink link:calculationLink link:definitionLink 996085 - Disclosure - STOCK-BASED COMPENSATION AWARDS - SUMMARY OF OPTION ACTIVITY (Details) link:presentationLink link:calculationLink link:definitionLink 996095 - Disclosure - STOCK-BASED COMPENSATION AWARDS - SUMMARY OF NON-VESTED STOCK OPTION (Details) link:presentationLink link:calculationLink link:definitionLink 996105 - Disclosure - STOCK-BASED COMPENSATION AWARDS - Summary of RSU Activity (Details) link:presentationLink link:calculationLink link:definitionLink 996115 - Disclosure - WARRANTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 996125 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE ASSUMPTION OF WARRANTS (Details) link:presentationLink link:calculationLink link:definitionLink 996135 - Disclosure - SCHEDULE OF FAIR VALUE OF DERIVATIVE LIABILITY (Details) link:presentationLink link:calculationLink link:definitionLink 996145 - Disclosure - DERIVATIVE LIABILITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 996155 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 996165 - Disclosure - SUBSEQUENT EVENTS - Consolidated Statements of Operations and Comprehensive Loss (Details) link:presentationLink link:calculationLink link:definitionLink XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover - USD ($)	12 Months Ended
Cover - USD ($)	Dec. 31, 2023	Mar. 08, 2024	Jun. 30, 2023
Cover [Abstract]
Document Type	10-K/A
Amendment Flag	true
Amendment Description	Corbus Pharmaceuticals Holdings, Inc. (the “Company”) is filing this Amendment No. 1 (this “Amendment No. 1”) to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Original Form 10-K”), filed with the Securities and Exchange Commission (the “SEC”) on March 12, 2024, only for the purpose of amending and restating Item 11 of Part III of the Original Form 10-K to include certain information which was inadvertently omitted in the Original Form 10-K.In addition, pursuant to SEC rules, Item 15 of Part IV of the Original Form 10-K is hereby amended solely to include, as Exhibits 31.1 and 31.2, new certifications of our principal executive officer and principal financial officer pursuant to Rule 13a-14(a) under the Exchange Act of 1934 (the “Exchange Act”). Because no financial statements are included in this Amendment No. 1 and this Amendment No. 1 does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4, and 5 of such certifications have been omitted. We are not including new certifications required by Rule 13a-14(b) under the Exchange Act as no financial statements are included in this Amendment No. 1.Except for the changes to Item 11 of Part III and the filing of related certifications added to the list of Exhibits in Item 15 of Part IV, this Amendment No. 1 makes no changes to the Original Form 10-K.In addition, no other information has been updated for any subsequent events occurring after March 12, 2024, the date of the filing of the Original Form 10-K. Accordingly, this Amendment No. 1 should be read in conjunction with the Original Form 10-K and our other filings made with the SEC subsequent to the filing of the Original Form 10-K. Unless the context otherwise requires, references in this Amendment No. 1 to “Corbus,” the “Company,” “we,” “us,” or “our” mean Corbus Pharmaceuticals Holdings, Inc. and its subsidiaries unless we state otherwise, or the context otherwise indicates.
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-37348
Entity Registrant Name	Corbus Pharmaceuticals Holdings, Inc.
Entity Central Index Key	0001595097
Entity Tax Identification Number	46-4348039
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	500 River Ridge Drive
Entity Address, City or Town	Norwood
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02062
City Area Code	617
Local Phone Number	963-0100
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	CRBP
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 34,571,068
Entity Common Stock, Shares Outstanding		10,493,108
ICFR Auditor Attestation Flag	false
Documents Incorporated by Reference	None.
Auditor Firm ID	274
Auditor Location	Iselin, New Jersey
Auditor Name	EisnerAmper LLP

EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( $6)=%@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !%B718T63M3>X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M3L,P#(9?!>7>.DTG#E'7"X@32$A, G&+'&^+:)HH,6KW]K1EZX3@ 3C&_O/Y ML^0&H\:0Z#F%2(D=Y9O1=WW6&+?BR!PU0,8C>9/+*=%/S7U(WO#T3 >(!C_, M@4!)>0N>V%C#!F9@$5>B:!N+&A,9#NF,M[CBXV?J%IA%H(X\]9RA*BL0[3PQ MGL:N@2M@AC$EG[\+9%?B4OT3NW1 G)-C=FMJ&(9RJ)?LS MFQYI^I6=YE.DK;A,?JWO[G7F?7;]X7<5]L&ZO?O' MQA?!MH%?=]%^ 5!+ P04 " !%B718F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M $6)=%CH$")@!@L *L\ 8 >&PO=V]R:W-H965T&UL MM9MK<^(X%H;_BHJ9FNJI"N +N74GJ2*0S##=G7G;,.BLD<9XE\8)L_25&A8Z47 ML43HOVB3__8X[* H$Y*MBF HP8JF^7_\5(#8"CCS6@*"(B!X$> /6@+"(B#< M-V!0! PTF;PJFL,82WQUP=D&1PED*6Z[_M#$R%KW*&$'(DU"!U7A(ZM M51P"GE@CNDWPPH3('B]Y9@([LD8="LB16 /0207H9$] 8R(B3M?J7F/B9)<9 M,3[+!+I?8KC31"23-,*)0'^R)*;I0ARA20I3UANY).BW7\Z"P'LW8JLU3I_U M-__=[X@*-*<@NT!R"9_KC*KZP"F8 MJZ,E\H-\LCZ"0\ES5>IUQM=,$,3F""LDBIZZ!G03B:7Z-I$$BN>K7]QCJ/QD M,E&?5?#/55#\:!HE64Q01+B$G B^YYF3*N9F2:$L&RS@*(YATI;0!% U13Q+B.HANJC'=5&_6DH*?6%).)D] MYQ6'BPN6$"A+784C! 6]>5K2&94"6K'G:S;P 6"FD&ZI*M(Y=%15+*$NQC*. MUASBZ1JN1IZ@Y53.!:?@9] 55'Q]?@YE@H_PJ3R_7;,'J!7R0]SU!V_P[RB# M0N:-5G6 82351?WS<-#H =L_*+M"#UV3"&?0UBG;NK!J9J(& O0M3LJ:%RUA M&$6J L83,8/NF3*)(LA45+M##]-D(>09Q3 Z$B8RN(3NUM"_UI"5JFJJ5@.Z MWFD.USM357H@BRS)^\RT^QY:''.\X'@-*5!XA* 7J]_JEA89]*@7#;'$@'Q& M2%IVK![Z1G3]5 'S.JJ^;6A#3O[)* < T#&V&V#6V@!8_%]$>R!&UK(:D;FR M*,F\''HY?U+.='"*$P %^B\J J,%#A;S64*%[BE59X;"_#Q:CLPMN\(_=--N M%VV?40H1#'['&S/ $G#IELG6L2ZVJK?J(2*;"6"O+DL>-3T6P;3']8PTER#S MQ9%D"C4^0,G@*$W3G_V9I;J"J&=DP MGZB&4:,_KW)>%@'L8K(UD<-?> T46>9'Z9#16D[+$P M_X&;@QDMC8AH';YPR>KNJ>ZW1\7T@'Z^KU:GBL,;\O+(5C@T8G$0&)0'5P2G M:+_[NJ*G^J6B0V.*N;K997FU-R0?4W6=CU Y6'ZB0>$>!D. B)XIZ;*F((Z7MS"_7ZCK9*K4EL:T7,/XC8 M=V6;VGG9Q=IZF#WL8&*.U)K$@II88/?'D N]!&8;GCODNET_Z(:^$9LU\F!L MCM2:V.J50=^Z?'9UDTHJGX$:I/)WF;+C1EAV$<_SN^%I.#@SXG*Z&.A*K8FK M7@[T[0MZ!2ZP7U2MI:J\$4R<$9E=:*^TSXC3Z/!N!VJ4\Z(3'Y\?>^:F1FM/E1%=J36KU@J)O7PHLJ'W&3V@2 M [K*U=I&L%UR<-(=P/CUPG,C/:>^P)5:DU[M#'Q[2E_0@_'%..2Y.#?CT]Q! M MD993%^%*K4FK=A&!/?G_3&6BE^7]0&V<%/N7QJQWAY+:XE1[0))%/_0N$'K$ M24;0KUY/)<1H#;=4 1[#>#.U:Q_,]#6L1%!;B<">_W_F6.]939]7,Y884=H% M1@_7]T9*3JV#*[4FI=HZ!/8\O^QJ]19=FW_=(70WG(Z'_S+R=5F M(=C++'PC2=+]D4)>!H,5"YCE8C01(FN9YNR:=\R(S:E%<*76Q%9;A& OB_"5 M)6"F,,_7E[AQ[7*'4@LLIS; E5H35FT#@KUL0+F F>^^Z*D,$EOS@N\.Q>_$ M%#6R1QU,[35<0%B[@' O%S!))>'Y@[MJJ1>7&(V/.-H56ZC9HPY^F/$U3$!8 MFX!P+Q.@AR,:@6]:,&[,.W;HW+&TBZ.(@(Q^2D$+&NDYM0*NU)KT:BL0VC/Y M@MYTA9,$76<"3@OC^-RAT[:K; \[&-9K6()PZYGCO786;E:$+]1L]@V7Z8=IE-3X$JM";,V!>%>^PO3)>1OUIYGEVF'Y=0;N%)KPJJ]0;C7 MML)]-DMHA&X3ALUW49?Y_R=G%_U'$YW:"81[ M.8&FX9XJ:RW0ITP*B?73P49B+E/[4:%VLE5'WQNCVP#F]Y46"'7OLH=.H&7*DUJ=5N(-SO$2.QM4-5 M/&Y;/KYH9+=K;R EQNUD>]S![%[#$PQJ3S"P9_!E9[NE?(4F8Q.G'0K!J>EU MK9$]ZN#7=5[# PQJ#S"PY^XE);5FV_8NR@Z)B2!PZ C=D0WZ"XR]<<=^9!MF.\!LJ4L*'*[4@^^&#<:'1KG P+J?9?W_K[4Z5 MT.NW9 6*U&9Y_J)G=;1Z$W>HWS_MUS_/7^/]B)4?$"@AJ=PM^;YF['Y M%\G6^EW1&9.2K?3')<$QX>H'<'[.F"R_J M4[R=?_0]02P,$% @ 18ET M6++WPF_N @ B0X T !X;"]S='EL97,N>&ULW5=M:]LP$/XKQAVCA3$G M\>;&JV/8#(7!.@KMAWTK2BP[ EGR9+ES^NNGLQSGI;JR]G MLT221F\XO5E3JKVNXJ)9^&NMZP]!T*S6M"+-6UE389!"JHIH,U1ET-2*DKP! MIXH'L\DD"BK"A)\FHJTN*]UX*]D*O?"GH\FSS>?<&*-WOF?#93*G"__N]/7W M5NJ+5YYM3]Z0-_=M-;126BFRFL_?^SJ%O#,E2JIRJ M@[Q;4YIP6H LQ=$S8%>7\!@KD6W$0NROV M]G,"NRG&KA$T=&T8.X#X^]%L[+VPY\\*Z]7L7NI/K5F-Z,=0*/1:T8)U_;@K M1GXL^A2/3NJ:;SYR5HJ*VK7_,F&:D*V?MY:*/1@VJ)25,5#E>_=4:;;:M_Q0 MI+ZEG=Y64U?@FF?_H.8_F^>2"JH(WQ=M2O\E9_G9BH<#]6]H[D^58\5.D>'Y MB]08#,?0WEEW<-*-5@]NE(7_%>XMOB/UEBWCFHEAM&9Y3L6C \^$UV1I[MF# M^&9^3@O2)QU#8D89NWZ7V!YTVB\S@P7$SGM:)X-0U4N M^ZYG.H9U>,#A&+GL'S>"^5C,C0"&\6 *,!_KA?'\3^N9H^NQ&*9M[D3FJ,\< M];%>+B3K/QB/VR]/]A;$H9Q[$8 -8?2 M0$3;8T.P6BP^0"X99K>]9!:G%C:^?VZH:TE[VE-S9NMQ=%A?BTX'HE'QY%V)N:I%FGJ:Q MJ,';>$<-!)U4Q-Z*0CZFL6&P9:P!Q+MTFF6SU%L,9KD8M;:X1+_)UW,#ECQ ,ZE._<]'<')O$8T.,5RMQD)HDU75Z(\4I!K-L53,[E9C(, M]L""Q1]ZUYG\M(?8,V(/'U:-Y&:6J6"%'*7?Z/6M>CR#+@^H%7I")\!K*_#, MU#88CIV,IDAO8O0]C.=0XIS_4R-5%1:PIJ+U$&3HD<%U!D.LL8DF"=9#;E9T M!N[RZ .;O\P>=0> M6N=6RKV'5[+E&''\GN4/4$L#!!0 ( $6)=%@D'INBK0 /@! : M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q= M6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ MI%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*'3^ 5!+ P04 " !%B71899!YDAD! #/ P M$P %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M= M< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4' M3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!- MFI6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXP MC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T, M:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0 ( M $6)=%@'04UB@0 +$ 0 " 0 !D;V-0&UL4$L! A0#% @ 18ET6-%D[4WN *P( !$ M ( !KP &1O8U!R;W!S+V-O&UL4$L! A0#% @ 18ET6)E&PO=V]R:W-H965T&UL4$L! A0#% @ 18ET6++WPF_N M @ B0X T ( !21, 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% @ 18ET6"0>FZ*M M^ $ !H ( !JQ@ 'AL+U]R96QS+W=O9(9 0 SP, !, ( ! MD!D %M#;VYT96YT7U1Y<&5S72YX;6Q02P4& D "0 ^ @ VAH end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 3 39 1 false 0 0 false 2 false false R1.htm 100000 - Document - Cover Sheet http://corbuspharma.com/20231231/taxonomy/role/Cover Cover Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate - crbp-20231231.htm 8 [DQC.US.0062.7501] The filing includes a cash flow statement in the role http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows, but does not report a value for the change in cash using any of the following elements: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect (After adoption of ASU-2016-18) CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect (After adoption of ASU-2016-18) CashPeriodIncreaseDecrease (Prior to adoption of ASU-2016-18) CashPeriodIncreaseDecreaseExcludingExchangeRateEffect (Prior to adoption of ASU-2016-18) CashAndCashEquivalentsPeriodIncreaseDecrease (Prior to adoption of ASU-2016-18) CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectDisposalGroupIncludingDiscontinuedOperations CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect (Prior to adoption of ASU-2016-18) or NetCashProvidedByUsedInContinuingOperations (As long as the element NetCashProvidedByUsedInDiscontinuedOperations is also included the reconciliation between opening and closing cash) If you have disclosed a change in cash for the period, one of the above elements should be used. Please update your filing if one of the following has occurred: 1. The change in cash has not been represented with a value, in this case the element should be tagged with a value of zero. 2. The change in cash flow is dimensionally qualified with an inappropriate dimension. The instance should have a value reported with no dimensions. The rule will identify where the successor member has been used or an extension member. The value for change in cash should not have a dimension. 3. The change in cash has been represented with an extension element. There is no reason the change in cash needs to be identified using an extension element. - crbp-20231231.htm - crbp-20231231.htm crbp-20231231.htm crbp-20231231.xsd http://xbrl.sec.gov/dei/2023 false false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "crbp-20231231.htm": { "nsprefix": "crbp", "nsuri": "http://corbuspharma.com/20231231", "dts": { "inline": { "local": [ "crbp-20231231.htm" ] }, "schema": { "local": [ "crbp-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] } }, "keyStandard": 39, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 4, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 3, "entityCount": 1, "segmentCount": 0, "elementCount": 787, "unitCount": 2, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 39 }, "report": { "R1": { "role": "http://corbuspharma.com/20231231/taxonomy/role/Cover", "longName": "100000 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_bf92528a-70f4-4342-8b3a-9874dc6fd82a", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "crbp-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bf92528a-70f4-4342-8b3a-9874dc6fd82a", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "crbp-20231231.htm", "first": true, "unique": true } } }, "tag": { "country_AU": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "AU", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfComponentsNetLossDetails" ], "lang": { "en-us": { "role": { "label": "AUSTRALIA" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountingStandardsUpdate201602Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingStandardsUpdate201602Member", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "Accounting Standards Update 2016-02 [Member]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/AccruedExpenses" ], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "ACCRUED EXPENSES" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "totalLabel": "Accounts Payable, Current, Total", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "auth_ref": [] }, "crbp_AccretionOfDebtDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "AccretionOfDebtDiscount", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureNotesPayableScheduleOfNotesPayableDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureNotesPayableScheduleOfNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accretion of debt discount", "label": "Accretion of Debt Discount", "documentation": "Accretion of Debt Discount." } } }, "auth_ref": [] }, "crbp_AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Accruals for Research and Development Expenses and Clinical Trials", "documentation": "Accruals for Research and Development Expenses and Clinical Trials [Policy Text Block]", "terseLabel": "Accruals for Research and Development Expenses and Clinical Trials" } } }, "auth_ref": [] }, "crbp_AccruedAdministrativeCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "AccruedAdministrativeCosts", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued administrative costs", "label": "Accrued administrative costs", "documentation": "Accrued administrative costs" } } }, "auth_ref": [] }, "crbp_AccruedClinicalOperationsAndTrialsCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "AccruedClinicalOperationsAndTrialsCostsCurrent", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued pre-clinical and clinical costs", "label": "Accrued clinical operations and trials costs", "documentation": "Accrued clinical operations and trials costs current." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAccruedExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAccruedExpensesDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses" } } }, "auth_ref": [] }, "crbp_AccruedPreClinicalCost": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "AccruedPreClinicalCost", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureLicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Accrued pre-clinical cost", "label": "Accrued pre-clinical cost" } } }, "auth_ref": [] }, "crbp_AccruedProductDevelopmentCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "AccruedProductDevelopmentCostsCurrent", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued product development costs", "documentation": "Accrued product development costs current.", "terseLabel": "Accrued product development costs" } } }, "auth_ref": [] }, "us-gaap_AccruedRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedRoyaltiesCurrent", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrued Royalties, Current" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/SummaryOfPropertyAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total", "negatedLabel": "Less: accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity1" ], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r40" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "periodEndLabel": "Additional Paid in Capital, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Beginning Balance", "totalLabel": "Additional Paid in Capital, Total", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity1" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "auth_ref": [] }, "crbp_AdditionalSharesOfCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "AdditionalSharesOfCommonStock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/LiquidityDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "additional shares of common stock", "label": "additional shares of common stock", "terseLabel": "Additional shares of common stock" } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r46" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r46" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r46" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r46" ] }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Axis]" } } }, "auth_ref": [] }, "crbp_AdjustmentsToAdditionalPaidInCapitalIncreaseInFairValueOfConversionOption": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "AdjustmentsToAdditionalPaidInCapitalIncreaseInFairValueOfConversionOption", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in fair value of conversion option", "label": "Adjustments to Additional Paid in Capital, increase in fair value of conversion option", "documentation": "Adjustments to Additional Paid in Capital, increase in fair value of conversion option" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity1" ], "lang": { "en-us": { "role": { "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity1" ], "lang": { "en-us": { "role": { "verboseLabel": "Increase in the fair value", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Fair value of warrants issued" } } }, "auth_ref": [] }, "crbp_AdjustmentsToAdditionalPaidInCapitaldFairValueOfWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "AdjustmentsToAdditionalPaidInCapitaldFairValueOfWarrantIssued", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair value of warrants issued", "documentation": "Fair value of warrant issued.", "label": "AdjustmentsToAdditionalPaidInCapitaldFairValueOfWarrantIssued", "terseLabel": "Fair value of warrants issued" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r10", "r22", "r32", "r58" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r13", "r25", "r35", "r61" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r46" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r53" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r17", "r26", "r36", "r53", "r62", "r66", "r74" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r72" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsScheduleOfStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Share-based Payment Arrangement, Expense" } } }, "auth_ref": [] }, "crbp_AmendedLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "AmendedLoanAgreementMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "Amended loan agreement", "label": "Amended loan agreement [Member]", "documentation": "Amended loan agreement [Member]" } } }, "auth_ref": [] }, "crbp_AmendedPremisesMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "AmendedPremisesMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Amended Premises [Member]", "documentation": "Amended Premises [Member]", "terseLabel": "Amended Premises [Member]" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Description", "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of debt discount" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]" } } }, "auth_ref": [] }, "crbp_AprilTwoThousandAndTwentySaleAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "AprilTwoThousandAndTwentySaleAgreementMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "April 2020 Sale Agreement [Member]", "documentation": "April 2020 Sale Agreement [Member]", "terseLabel": "April 2020 Sale Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_AreaOfLand": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AreaOfLand", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Area of Land", "terseLabel": "Area of office space" } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DerivativeLiabilityDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureLicenseAgreementDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/LiquidityDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "auth_ref": [] }, "crbp_AssetAcquisitionsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "AssetAcquisitionsPolicyPolicyTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition", "label": "Asset Acquisitions, Policy [Policy Text Block]", "documentation": "Asset Acquisitions, Policy [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_AssetBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetBackedSecuritiesMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSummaryOfInvestmentsDetails", "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Asset-Backed Securities [Member]", "terseLabel": "Asset-backed Securities [Member]" } } }, "auth_ref": [] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetImpairmentCharges", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "totalLabel": "Asset Impairment Charges, Total", "label": "Asset Impairment Charges", "terseLabel": "Impairment charges" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure", "terseLabel": "Assets, Fair Value", "totalLabel": "Assets, Fair Value, Total" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r4", "r5", "r18" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r4", "r5", "r18" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r4", "r5", "r18" ] }, "crbp_AugustTwentyTwentySaleAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "AugustTwentyTwentySaleAgreementMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/LiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "August 2020 Sale Agreement [Member]", "documentation": "August 2020 Sale Agreement [Member]", "terseLabel": "August 2020 Sale Agreement [Member]" } } }, "auth_ref": [] }, "crbp_AugustTwoThousandAndTwentySaleAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "AugustTwoThousandAndTwentySaleAgreementMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "August 2020 Sale Agreement [Member]", "documentation": "August 2020 Sale Agreement [Member]", "label": "August 2020 Sale Agreement [Member] [Default Label]" } } }, "auth_ref": [] }, "crbp_AugustTwoThousandSeventeenLeaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "AugustTwoThousandSeventeenLeaseAgreementMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "August 2017 Lease Agreement [Member]", "documentation": "August 2017 Lease Agreement [Member]", "terseLabel": "August 2017 Lease Agreement [Member]" } } }, "auth_ref": [] }, "crbp_AuthorizedToOfferAndSellUpOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "AuthorizedToOfferAndSellUpOfCommonStock", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/LiquidityDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Authorized to offer and sell up of common stock", "documentation": "Authorized to offer and sell up of common stock." } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSummaryOfInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSummaryOfInvestmentsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureInvestmentsSummarizesTheAmortizedCostAndFairValueDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureInvestmentsSummarizesTheAmortizedCostAndFairValueDetails", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSummaryOfInvestmentsDetails", "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAvailableForSaleDebtSecuritiesByContractualMaturityDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Amortized Cost", "verboseLabel": "Amortized Cost", "totalLabel": "Debt Securities, Available-for-sale, Amortized Cost" } } }, "auth_ref": [] }, "crbp_AvailableForSaleOtherInvestmentsAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "AvailableForSaleOtherInvestmentsAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSummaryOfInvestmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Available For Sale Other Investments Accumulated Gross Unrealized Gain Before Tax", "label": "Available For Sale Other Investments Accumulated Gross Unrealized Gain Before Tax", "terseLabel": "Other Investments, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax" } } }, "auth_ref": [] }, "crbp_AvailableForSaleOtherInvestmentsAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "AvailableForSaleOtherInvestmentsAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSummaryOfInvestmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Available For Sale Other Investments Accumulated Gross Unrealized Loss Before Tax", "label": "Available For Sale Other Investments Accumulated Gross Unrealized Loss Before Tax", "terseLabel": "Other Investments, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax" } } }, "auth_ref": [] }, "crbp_AvailableForSaleOtherInvestmentsAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "AvailableForSaleOtherInvestmentsAmortizedCostBasis", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSummaryOfInvestmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Available for Sale Other Investments Amortized Cost Basis.", "label": "Available for Sale Other Investments Amortized Cost Basis", "terseLabel": "Other Investments, Available-for-sale, Amortized Cost" } } }, "auth_ref": [] }, "crbp_AvailableForSaleOtherInvestmentsAndDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "AvailableForSaleOtherInvestmentsAndDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSummaryOfInvestmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Available For Sale Other Investments and Debt Securities Accumulated Gross Unrealized Gain Before Tax.", "label": "Available For Sale Other Investments and Debt Securities Accumulated Gross Unrealized Gain Before Tax", "terseLabel": "Other Investments and Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax" } } }, "auth_ref": [] }, "crbp_AvailableForSaleOtherInvestmentsAndDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "AvailableForSaleOtherInvestmentsAndDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSummaryOfInvestmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Available For Sale Other Investments And Debt Securities Accumulated Gross Unrealized Loss Before Tax", "label": "Available For Sale Other Investments And Debt Securities Accumulated Gross Unrealized Loss Before Tax", "terseLabel": "Other Investments and Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax" } } }, "auth_ref": [] }, "crbp_AvailableForSaleOtherInvestmentsAndDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "AvailableForSaleOtherInvestmentsAndDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSummaryOfInvestmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Available for Sale Other Investments And Debt Securities Amortized Cost Basis.", "label": "Available for Sale Other Investments And Debt Securities Amortized Cost Basis", "terseLabel": "Other investments and Debt Securities, Amortized Cost Basic" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureInvestmentsSummarizesTheAmortizedCostAndFairValueDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureInvestmentsSummarizesTheAmortizedCostAndFairValueDetails", "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAvailableForSaleDebtSecuritiesByContractualMaturityDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureInvestmentsSummarizesTheAmortizedCostAndFairValueDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureInvestmentsSummarizesTheAmortizedCostAndFairValueDetails", "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAvailableForSaleDebtSecuritiesByContractualMaturityDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureInvestmentsSummarizesTheAmortizedCostAndFairValueDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureInvestmentsSummarizesTheAmortizedCostAndFairValueDetails", "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAvailableForSaleDebtSecuritiesByContractualMaturityDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureInvestmentsSummarizesTheAmortizedCostAndFairValueDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureInvestmentsSummarizesTheAmortizedCostAndFairValueDetails", "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAvailableForSaleDebtSecuritiesByContractualMaturityDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureInvestmentsSummarizesTheAmortizedCostAndFairValueDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureInvestmentsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureInvestmentsSummarizesTheAmortizedCostAndFairValueDetails", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSummaryOfInvestmentsDetails", "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAvailableForSaleDebtSecuritiesByContractualMaturityDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale", "verboseLabel": "Fair Value", "totalLabel": "Debt Securities, Available-for-sale, Fair Value" } } }, "auth_ref": [] }, "crbp_AvailableForSaleSecuritiesOtherInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "AvailableForSaleSecuritiesOtherInvestments", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSummaryOfInvestmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Available for Sale Securities Other Investments", "label": "Available for Sale Securities Other Investments", "terseLabel": "Other Investments, Available-for-sale" } } }, "auth_ref": [] }, "crbp_AvailableForSaleSecuritiesOtherInvestmentsAndDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "AvailableForSaleSecuritiesOtherInvestmentsAndDebtSecurities", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSummaryOfInvestmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Available for Sale Securities Other Investments And Debt Securities", "label": "Available for Sale Securities Other Investments And Debt Securities", "terseLabel": "Other Investments and Debt Securities, Available-for-sale" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r69" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r70" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r65" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r65" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r65" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r65" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r65" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r65" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsDetailsNarrative", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "auth_ref": [] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r68" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r67" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r66" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r66" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureLicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "totalLabel": "Business Combination, Consideration Transferred, Total", "label": "Business Combination, Consideration Transferred", "terseLabel": "Upfront cash payment" } } }, "auth_ref": [] }, "crbp_CFFWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "CFFWarrantMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfWeightedAverageAssumptionOfWarrantsDetails", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsTables" ], "lang": { "en-us": { "role": { "label": "CFF Warrant [Member]", "documentation": "CFF Warrant [Member]", "terseLabel": "CFF Warrant [Member]" } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchases of property and equipment included in accounts payable or accrued expenses" } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Cash", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails": { "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Cash, Ending Balance", "periodStartLabel": "Cash, Beginning Balance", "label": "Cash", "terseLabel": "Cash" } } }, "auth_ref": [] }, "crbp_CashAndCashEquivalentsAndInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "CashAndCashEquivalentsAndInvestments", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Cash And Cash Equivalents And Investments.", "label": "Cash And Cash Equivalents And Investments", "terseLabel": "Cash, cash equivalents and investments" } } }, "auth_ref": [] }, "crbp_CashAndCashEquivalentsAndMarketableDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "CashAndCashEquivalentsAndMarketableDebtSecurities", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/LiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, cash equivalents and marketable debt securities", "documentation": "Cash, cash equivalents and marketable debt securities.", "label": "Cash, cash equivalents and marketable debt securities" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 }, "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "totalLabel": "Cash and cash equivalents", "verboseLabel": "Cash and Cash Equivalents, at Carrying Value", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash Equivalents, Fair Value" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash, Cash Equivalents, and Restricted Cash" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance", "periodStartLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "totalLabel": "Total cash, cash equivalents, and restricted cash shown in the statement of cash flows" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total", "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of the period", "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of the period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect" } } }, "auth_ref": [] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails": { "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Cash Equivalents, at Carrying Value, Total", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash Equivalents" } } }, "auth_ref": [] }, "crbp_CashHeldInSubsidiary": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "CashHeldInSubsidiary", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash held in subsidiary", "documentation": "Cash held in subsidiary.", "terseLabel": "Cash held in subsidiary" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r44" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity1" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfWeightedAverageAssumptionOfWarrantsDetails", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsTables" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfWeightedAverageAssumptionOfWarrantsDetails", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsTables" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "verboseLabel": "Warrant exercisable price per share", "terseLabel": "Exercise price of warrants" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/WarrantsTables" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/WarrantsTables" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r45" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r45" ] }, "crbp_CollaborationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "CollaborationAgreementMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaboration Agreement [Member]", "documentation": "Collaboration Agreement [Member]" } } }, "auth_ref": [] }, "crbp_CollaborationandLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "CollaborationandLicenseAgreementMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaboration and License Agreement [Member]", "documentation": "Collaboration and License Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DerivativeLiabilityDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureLicenseAgreementDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/LiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "auth_ref": [] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSummaryOfInvestmentsDetails", "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper [Member]" } } }, "auth_ref": [] }, "crbp_CommissionPercentage": { "xbrltype": "percentItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "CommissionPercentage", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/LiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Commission percentage", "documentation": "Commission percentage." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Shares available for future issuance" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity1" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/LiquidityDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "totalLabel": "Common Stock, Shares, Issued, Total", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common Shares" } } }, "auth_ref": [] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "totalLabel": "Common Stock, Value, Issued, Total", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.0001 par value; 300,000,000 shares authorized, 4,423,683 and 4,171,297 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r50" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r49" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r51" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r48" ] }, "crbp_CompanysCorporateCreditCardsMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "CompanysCorporateCreditCardsMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Company's Corporate Credit Cards [Member]", "documentation": "Company's Corporate Credit Cards [Member]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations2": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSubsequentEventsConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive loss" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSubsequentEventsConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Comprehensive loss:" } } }, "auth_ref": [] }, "crbp_ComputerHardwareAndSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "ComputerHardwareAndSoftwareMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Computer Hardware and Software [Member]", "documentation": "Computer Hardware and Software [Member]", "terseLabel": "Computer Hardware and Software [Member]" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations of Credit Risk" } } }, "auth_ref": [] }, "crbp_ConsecutiveBusinessDays": { "xbrltype": "integerItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "ConsecutiveBusinessDays", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Consecutive business days", "label": "Consecutive business days", "terseLabel": "Consecutive business days" } } }, "auth_ref": [] }, "crbp_ConsiderationReceivableOnMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "ConsiderationReceivableOnMilestonePayments", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Consideration receivable on milestone payments", "documentation": "Consideration receivable on milestone payments.", "terseLabel": "Consideration payment milestone received" } } }, "auth_ref": [] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Consolidation, Policy [Policy Text Block]", "verboseLabel": "Consolidation" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueTables" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "SCHEDULE OF ROLL FORWARD OF DEFERRED REVENUE" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetNet", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "totalLabel": "Contract with Customer, Asset, after Allowance for Credit Loss, Total", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "terseLabel": "Contract asset" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetSale": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetSale", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Contract asset", "label": "Contract with Customer, Asset, Sale" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Current", "terseLabel": "Revenue from related parties, recorded as deferred revenue" } } }, "auth_ref": [] }, "crbp_ContractWithCustomerLiabilityReclassificationToContractAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "ContractWithCustomerLiabilityReclassificationToContractAsset", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueScheduleOfRollForwardOfDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Reclassification to contract asset", "documentation": "Contract with customer liability, reclassification to contract asset." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueScheduleOfRollForwardOfDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Recognition of revenue", "verboseLabel": "Contract with Customer, Liability, Revenue Recognized" } } }, "auth_ref": [] }, "us-gaap_ConversionOfStockAmountIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockAmountIssued1", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity1" ], "lang": { "en-us": { "role": { "label": "Conversion of Stock, Amount Issued", "terseLabel": "Issuance of common stock upon conversion of K2 Loan and Security Agreement, Value" } } }, "auth_ref": [] }, "us-gaap_ConversionOfStockSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockSharesIssued1", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity1" ], "lang": { "en-us": { "role": { "label": "Conversion of Stock, Shares Issued", "terseLabel": "Issuance of common stock upon conversion of K2 Loan and Security Agreement, Shares" } } }, "auth_ref": [] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateDebtSecuritiesMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSummaryOfInvestmentsDetails", "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Debt Securities [Member]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]" } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]" } } }, "auth_ref": [] }, "crbp_CspcLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "CspcLicenseAgreementMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureLicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Cspc License Agreement [Member]", "label": "Cspc License Agreement [Member]" } } }, "auth_ref": [] }, "crbp_CspcMegalithBiopharmaceuticalCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "CspcMegalithBiopharmaceuticalCoLtdMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "CSPC Megalith Biopharmaceutical Co., Ltd. [Member]", "label": "CSPC Megalith Biopharmaceutical Co., Ltd. [Member]", "documentation": "CSPC Megalith Biopharmaceutical Co., Ltd. [Member]" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "crbp_CysticFibrosisFoundationMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "CysticFibrosisFoundationMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cystic Fibrosis Foundation [Member]", "documentation": "Cystic Fibrosis Foundation [Member]" } } }, "auth_ref": [] }, "crbp_CysticFibrosisFoundationWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "CysticFibrosisFoundationWarrantsMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cystic Fibrosis Foundation Warrants [Member]", "documentation": "Cystic Fibrosis Foundation warrants [Member]" } } }, "auth_ref": [] }, "crbp_CysticFibrosisProgramRelatedInvestmentAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "CysticFibrosisProgramRelatedInvestmentAgreementMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cystic Fibrosis Program Related Investment Agreement [Member]", "documentation": "Cystic Fibrosis Program Related Investment Agreement [Member]" } } }, "auth_ref": [] }, "crbp_Debt1AMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "Debt1AMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "Debt 1a [Member]", "label": "Debt 1a [Member]", "documentation": "Debt 1a [Member]" } } }, "auth_ref": [] }, "crbp_Debt1BMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "Debt1BMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "Debt 1b [Member]", "label": "Debt 1b [Member]", "documentation": "Debt 1b [Member]" } } }, "auth_ref": [] }, "crbp_Debt1Member": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "Debt1Member", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "Debt 1 [Member]", "label": "Debt 1 [Member]", "documentation": "Debt 1 [Member]" } } }, "auth_ref": [] }, "crbp_Debt2Member": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "Debt2Member", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "Debt 2 [Member]", "label": "Debt 2 [Member]", "documentation": "Debt 2 [Member]" } } }, "auth_ref": [] }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionConvertedInstrumentAmount1", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Conversion, Converted Instrument, Amount", "label": "Debt Conversion, Converted Instrument, Amount" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayable" ], "lang": { "en-us": { "role": { "terseLabel": "NOTES PAYABLE", "label": "Debt Disclosure [Text Block]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureNotesPayableScheduleOfNotesPayableDetails2": { "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0, "order": 0.0 }, "http://corbuspharma.com/20231231/taxonomy/role/DisclosureNotesPayableScheduleOfNotesPayableDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureNotesPayableScheduleOfNotesPayableDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net carrying amount", "label": "Long-Term Debt, Gross" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleBeneficialConversionFeature", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity1" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of debt conversion feature", "label": "Debt Instrument, Convertible, Beneficial Conversion Feature" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Conversion price per share" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentDescription", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Description", "label": "Debt Instrument, Description" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureNotesPayableScheduleOfNotesPayableDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureNotesPayableScheduleOfNotesPayableDetails", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "Principal", "label": "Debt Instrument, Face Amount", "verboseLabel": "Debt face amount" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage", "label": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureNotesPayableScheduleOfPrincipalMaturitiesOnLongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentMaturityDate", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Maturity Date", "label": "Debt Instrument, Maturity Date" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Periodic Payment", "totalLabel": "Debt Instrument, Periodic Payment, Total", "label": "Debt Instrument, Periodic Payment" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPeriodAxis", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureNotesPayableScheduleOfPrincipalMaturitiesOnLongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Redemption, Period [Axis]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPeriodDomain", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureNotesPayableScheduleOfPrincipalMaturitiesOnLongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Redemption, Period [Domain]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureNotesPayableScheduleOfPrincipalMaturitiesOnLongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]" } } }, "auth_ref": [] }, "crbp_DebtInstrumentTermDescription": { "xbrltype": "stringItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "DebtInstrumentTermDescription", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "Monthly loan payments term", "label": "Monthly loan payments term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureNotesPayableScheduleOfNotesPayableDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureNotesPayableScheduleOfNotesPayableDetails", "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Unamortized Discount", "totalLabel": "Debt Instrument, Unamortized Discount, Total", "negatedLabel": "Less: debt discount", "label": "Debt Instrument, Unamortized Discount" } } }, "auth_ref": [] }, "crbp_DebtIssuanceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "DebtIssuanceCost", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "Debt issuance cost", "label": "Debt issuance cost", "documentation": "Debt issuance cost." } } }, "auth_ref": [] }, "crbp_DecemberThirtyOneTwoThousandTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "DecemberThirtyOneTwoThousandTwentyFourMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureNotesPayableScheduleOfPrincipalMaturitiesOnLongTermDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "December Thirty One Two Thousand Twenty Four [Member]", "label": "December Thirty One Two Thousand Twenty Four [Member]", "terseLabel": "December 31, 2024" } } }, "auth_ref": [] }, "crbp_DecreaseInOperatingLeaseRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "DecreaseInOperatingLeaseRightOfUseAssets", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Decrease in operating lease right of use assets", "label": "Decrease in operating lease right of use assets", "terseLabel": "Decrease in operating lease right-of-use asset" } } }, "auth_ref": [] }, "crbp_DefaultLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "DefaultLoanAgreementMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "Event of Default - Loan Agreement [Member]", "label": "Event of Default - Loan Agreement [Member]", "documentation": "Event of Default - Loan Agreement [Member]" } } }, "auth_ref": [] }, "crbp_DeferredRevenueBillingToUponAchievementOfMilestone": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "DeferredRevenueBillingToUponAchievementOfMilestone", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueScheduleOfRollForwardOfDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Invoicing to CFF upon achievement of milestones", "documentation": "Billing to CFF upon achievement of milestone." } } }, "auth_ref": [] }, "us-gaap_DeferredRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenueCurrent", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueScheduleOfRollForwardOfDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred Revenue, Current, Total", "label": "Deferred Revenue, Current", "periodStartLabel": "Beginning balance, December 31, 2019", "periodEndLabel": "Ending balance, December 31, 2020" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfComponentsOfNetDeferredTaxAssetDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfComponentsOfNetDeferredTaxAssetDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Gross", "terseLabel": "Subtotal", "totalLabel": "Subtotal" } } }, "auth_ref": [] }, "crbp_DeferredTaxAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "DeferredTaxAssetsMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets [Member]", "documentation": "Deferred Tax Assets [Member]", "terseLabel": "Deferred Tax Assets [Member]" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfComponentsOfNetDeferredTaxAssetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfComponentsOfNetDeferredTaxAssetDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Net deferred tax asset" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfComponentsOfNetDeferredTaxAssetDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfComponentsOfNetDeferredTaxAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. and state net operating loss carryforwards", "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total", "label": "Deferred Tax Assets, Operating Loss Carryforwards" } } }, "auth_ref": [] }, "crbp_DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear": { "xbrltype": "gYearItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating loss carryforwards expiration year", "documentation": "Deferred tax assets operating loss carryforwards expiration year.", "terseLabel": "Operating loss carryforwards expiration year" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfComponentsOfNetDeferredTaxAssetDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfComponentsOfNetDeferredTaxAssetDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign", "terseLabel": "Foreign net operating loss carryforward" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfComponentsOfNetDeferredTaxAssetDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfComponentsOfNetDeferredTaxAssetDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Other", "terseLabel": "Other temporary differences" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfComponentsOfNetDeferredTaxAssetDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfComponentsOfNetDeferredTaxAssetDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Tax credit carryforward" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "terseLabel": "Research and development tax credit carryforwards" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfComponentsOfNetDeferredTaxAssetDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfComponentsOfNetDeferredTaxAssetDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "terseLabel": "Stock based compensation" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfComponentsOfNetDeferredTaxAssetDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfComponentsOfNetDeferredTaxAssetDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfComponentsOfNetDeferredTaxAssetDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfComponentsOfNetDeferredTaxAssetDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance" } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "totalLabel": "Depreciation, Total", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "auth_ref": [] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization" } } }, "auth_ref": [] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfNonvestedStockOptionDetails" ], "lang": { "en-us": { "role": { "label": "Derivative Contract [Domain]" } } }, "auth_ref": [] }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DerivativeLiabilityDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfFairValueOfDerivativeLiabilityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Derivative Liability, Fair Value, Gross Liability, Total", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "periodStartLabel": "Beginning balance, December 31, 2022", "periodEndLabel": "Ending balance, December 31, 2023", "terseLabel": "Derivative Liability, Fair Value" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfNonvestedStockOptionDetails" ], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DerivativeLiability" ], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "DERIVATIVE LIABILITY" } } }, "auth_ref": [] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilities", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Derivative Liability, Total", "label": "Derivative Liability", "terseLabel": "Liabilities, Fair Value" } } }, "auth_ref": [] }, "us-gaap_DerivativeLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Derivative Liability, Current", "terseLabel": "Derivative liability" } } }, "auth_ref": [] }, "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]" } } }, "auth_ref": [] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeTable", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfNonvestedStockOptionDetails" ], "lang": { "en-us": { "role": { "label": "Derivative [Table]" } } }, "auth_ref": [] }, "crbp_DisclosureLicenseAgreementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "DisclosureLicenseAgreementsAbstract", "lang": { "en-us": { "role": { "label": "License Agreements", "documentation": "Disclosure License Agreements Abstract" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAwards1" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "STOCK-BASED COMPENSATION AWARDS" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "crbp_DisclosureWarrantsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "DisclosureWarrantsAbstract", "lang": { "en-us": { "role": { "label": "Warrants", "documentation": "Disclosure Warrants Abstract" } } }, "auth_ref": [] }, "us-gaap_DividendsPayableAmountPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsPayableAmountPerShare", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend declared, per share", "label": "Dividends Payable, Amount Per Share" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "terseLabel": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r4", "r5", "r18" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r4", "r5", "r18", "r54" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "terseLabel": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r39" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r2" ] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DomesticCountryMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Domestic Tax Authority [Member]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfComputationOfNetLossPerCommonShareDetails", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSubsequentEventsConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Net loss per share, basic", "totalLabel": "Earnings Per Share, Basic, Total", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share basic" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSubsequentEventsConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share, diluted", "label": "Earnings Per Share, Diluted", "totalLabel": "Earnings Per Share, Diluted, Total" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted, Other Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss Per Common Share" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Effective Income Tax Rate Reconciliation, Percent, Total", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Total" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Tax provision at statutory rate" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfEffectiveIncomeTaxRateReconciliationDetails", "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "Change in valuation reserve", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent", "terseLabel": "Foreign income tax rate change" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "terseLabel": "Permanent differences" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Other" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent, Total", "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent", "terseLabel": "NOL Adjustments" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State income taxes, net of federal benefit", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent", "terseLabel": "Tax credits", "verboseLabel": "Tax credits" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsForeign", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent", "terseLabel": "Foreign expected tax" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Employee-related Liabilities, Current, Total", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsScheduleOfStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Total unrecognized compensation expense" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Share-based compensation expense, not yet recognized period of recognition" } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerCommonShareDetails", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfFairValueOfOptionsGrantedDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DerivativeLiabilityDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/LiquidityDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "terseLabel": "All Entities", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "terseLabel": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r1" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r79" ] }, "dei_EntityListingsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityListingsLineItems", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Entity Listings [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "terseLabel": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r1" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "terseLabel": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r80" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity1", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentQuotedMarketValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentQuotedMarketValue", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Method Investment, Quoted Market Value", "terseLabel": "Market value of listed securities" } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r47" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r10", "r22", "r32", "r58" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r7", "r19", "r29", "r55" ] }, "crbp_EstimatedIssuanceCostsIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "EstimatedIssuanceCostsIncurred", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Less estimated issuance costs incurred.", "label": "Estimated Issuance Costs Incurred", "terseLabel": "Estimated Issuance Costs Incurred" } } }, "auth_ref": [] }, "crbp_EvergreenProvisionMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "EvergreenProvisionMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Evergreen Provision [Member]", "documentation": "Evergreen Provision [Member]", "terseLabel": "Evergreen Provision [Member]" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r53" ] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair Value Adjustment of Warrants" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Asset Class [Domain]" } } }, "auth_ref": [] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByAssetClassAxis", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Asset Class [Axis]" } } }, "auth_ref": [] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "auth_ref": [] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilities" ], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES" } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Fair Value, Inputs, Level 1 [Member]" } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2 [Member]" } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Fair Value, Inputs, Level 3 [Member]" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring [Member]" } } }, "auth_ref": [] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Financial Instruments" } } }, "auth_ref": [] }, "crbp_FairValueOfWarrantsIssuedWithK2hvLoanAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "FairValueOfWarrantsIssuedWithK2hvLoanAgreement", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Fair value of warrants issued in loan agreement", "documentation": "Fair value of warrants issued with K2HV loan agreement.", "terseLabel": "Fair value of warrants issued with K2HV loan agreement" } } }, "auth_ref": [] }, "crbp_FebruaryTwoThousandAndNineteenLeaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "FebruaryTwoThousandAndNineteenLeaseAgreementMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "February 2019 Lease Agreement [Member]", "documentation": "February 2019 Lease Agreement [Member]", "terseLabel": "February 2019 Lease Agreement [Member]" } } }, "auth_ref": [] }, "crbp_FederalMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "FederalMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Federal [Member]", "documentation": "Federal [Member]", "terseLabel": "Federal [Member]" } } }, "auth_ref": [] }, "crbp_FinalPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "FinalPayment", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "Final payment", "label": "Final payment", "documentation": "Final payment." } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfUndiscountedSubleaseCashInflowsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfUndiscountedSubleaseCashInflowsDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid", "totalLabel": "Total sublease payments" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfUndiscountedSubleaseCashInflowsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfUndiscountedSubleaseCashInflowsDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid, Year One", "terseLabel": "2024" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfUndiscountedSubleaseCashInflowsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfUndiscountedSubleaseCashInflowsDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid, Year Three", "terseLabel": "2026" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfUndiscountedSubleaseCashInflowsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfUndiscountedSubleaseCashInflowsDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid, Year Two", "terseLabel": "2025" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSummaryOfInvestmentsDetails", "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]" } } }, "auth_ref": [] }, "crbp_FirstYearMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "FirstYearMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "First Year [Member]", "documentation": "First Year [Member]", "terseLabel": "First Year [Member]" } } }, "auth_ref": [] }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCountryMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign Tax Authority [Member]" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSubsequentEventsConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Foreign Currency Transaction Gain (Loss), before Tax, Total", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "terseLabel": "Foreign currency transaction gain (loss), net" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r14", "r26", "r36", "r62" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r14", "r26", "r36", "r62" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r14", "r26", "r36", "r62" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r14", "r26", "r36", "r62" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r14", "r26", "r36", "r62" ] }, "crbp_FourthAnniversaryMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "FourthAnniversaryMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fourth Anniversary [Member]", "documentation": "Fourth Anniversary [Member]", "terseLabel": "Fourth Anniversary [Member]" } } }, "auth_ref": [] }, "country_GB": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "GB", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfComponentsNetLossDetails", "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "UNITED KINGDOM", "terseLabel": "UNITED KINGDOM" } } }, "auth_ref": [] }, "us-gaap_GainContingencyUnrecordedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainContingencyUnrecordedAmount", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gain Contingency, Unrecorded Amount" } } }, "auth_ref": [] }, "crbp_GainLossOnForeignExchangeRate": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "GainLossOnForeignExchangeRate", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Gain on foreign exchange.", "label": "GainLossOnForeignExchangeRate", "negatedLabel": "(Gain) loss on foreign currency transaction" } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfDerivatives", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 }, "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DerivativeLiabilityDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSubsequentEventsConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfFairValueOfDerivativeLiabilityDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in fair value of derivative liability", "label": "Gain (Loss) on Sale of Derivatives", "negatedTerseLabel": "Change in fair value of derivative liabilities", "verboseLabel": "Gain (Loss) on Sale of Derivatives", "terseLabel": "Change in fair value of derivative liability" } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on sale of property and equipment", "totalLabel": "Gain (Loss) on Disposition of Property Plant Equipment, Total", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "terseLabel": "Loss on sale of property and equipment" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSubsequentEventsConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "General and Administrative Expense, Total", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsScheduleOfStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "terseLabel": "General And Administrative Expense [Member]" } } }, "auth_ref": [] }, "us-gaap_IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IPOMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "IPO [Member]", "terseLabel": "IPO [Member]" } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r4", "r5", "r18" ] }, "crbp_ImmediatelyExercisableWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "ImmediatelyExercisableWarrantsMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Immediately Exercisable Warrants [Member]", "documentation": "Immediately Exercisable Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-lived Assets" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureLicenseAgreementDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsScheduleOfStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureLicenseAgreementDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsScheduleOfStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Axis]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Domain]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureIncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized R&D costs", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 21.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Accounts Payable, Total", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Increase (decrease) in accounts payable" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 22.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Increase (decrease) in accrued expenses" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInContractWithCustomerAsset", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 17.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Contract with Customer, Asset", "negatedLabel": "Increase in other assets" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "crbp_IncreaseDecreaseInOperatingLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 25.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Decrease in operating lease liabilities", "documentation": "Increase decrease in operating lease liabilities.", "terseLabel": "Decrease in operating lease liabilities" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 18.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Other Operating Assets, Total", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "(Increase) decrease in prepaid expenses and other current assets" } } }, "auth_ref": [] }, "crbp_IncreaseDecreaseInRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "IncreaseDecreaseInRightOfUseAssets", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Increase in right of use assets", "documentation": "Increase in right of use assets.", "terseLabel": "Increase in right of use assets" } } }, "auth_ref": [] }, "crbp_IncreaseInOtherLongTermLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "IncreaseInOtherLongTermLiabilities", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 20.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Increase in other long-term liabilities", "documentation": "Increase in other long-term liabilities.", "label": "Increase In Other Long Term Liabilities", "verboseLabel": "Increase in other long-term liabilities" } } }, "auth_ref": [] }, "crbp_IndicationMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "IndicationMilestonePayments", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureLicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "Additional payment of indication milestone", "label": "Indication milestone payments", "documentation": "Indication milestone payments" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r17", "r26", "r36", "r53", "r62", "r66", "r74" ] }, "crbp_InitialMeasurementOfFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "InitialMeasurementOfFairValue", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfFairValueOfDerivativeLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Initial measurement of fair value", "documentation": "Initial measurement of fair value.", "terseLabel": "Initial measurement of fair value" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r72" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r6", "r78" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r6", "r78" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r6", "r78" ] }, "crbp_InstallmentOfLicenseIssuanceFee": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "InstallmentOfLicenseIssuanceFee", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureLicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Installment of license issuance fee", "documentation": "Installment of license issuance fee" } } }, "auth_ref": [] }, "crbp_InsurancePolicyMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "InsurancePolicyMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance Policy [Member]", "label": "Insurance Policy [Member]", "documentation": "Insurance Policy [Member]" } } }, "auth_ref": [] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Expense, Debt", "totalLabel": "Interest Expense, Debt, Total", "label": "Interest Expense, Debt" } } }, "auth_ref": [] }, "us-gaap_InterestIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeExpenseNet", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSubsequentEventsConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Interest Income (Expense), Net, Total", "label": "Interest Income (Expense), Net", "terseLabel": "Interest income (expense), net" } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid during the period for interest" } } }, "auth_ref": [] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPayableCurrent", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "label": "Interest Payable, Current" } } }, "auth_ref": [] }, "crbp_InvestmentAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "InvestmentAgreementMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Investment Agreement [Member]", "documentation": "Investment Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Investment Income, Net, Amortization of Discount and Premium, Total", "label": "Investment Income, Net, Amortization of Discount and Premium", "negatedLabel": "Net amortization on (discount) premium of investments" } } }, "auth_ref": [] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentPolicyTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments" } } }, "auth_ref": [] }, "us-gaap_InvestmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureInvestments" ], "lang": { "en-us": { "role": { "label": "Investment [Text Block]", "terseLabel": "INVESTMENTS" } } }, "auth_ref": [] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeAxis", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSummaryOfInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Investment Type [Axis]" } } }, "auth_ref": [] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeCategorizationMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSummaryOfInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Investments [Domain]" } } }, "auth_ref": [] }, "crbp_InvestmentagreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "InvestmentagreementsMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Investment Agreements [Member]", "documentation": "Investment Agreements [Member]" } } }, "auth_ref": [] }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureInvestmentsTables" ], "lang": { "en-us": { "role": { "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "terseLabel": "SCHEDULE OF AVAILABLE FOR SALE DEBT SECURITIES BY CONTRACTUAL MATURITY" } } }, "auth_ref": [] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Investments, Fair Value Disclosure, Total", "label": "Investments, Fair Value Disclosure", "terseLabel": "Marketable Securities, Fair Value" } } }, "auth_ref": [] }, "crbp_InvestorRelationsServiceProviderMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "InvestorRelationsServiceProviderMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Investor Relations Service Provider [Member]", "documentation": "Investor Relations Service Provider [Member]" } } }, "auth_ref": [] }, "crbp_IssuanceOfCommonStockForConversionOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "IssuanceOfCommonStockForConversionOfConvertibleDebt", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Issuance of common stock for conversion of convertible debt", "label": "Issuance of common stock for conversion of convertible debt", "terseLabel": "Issuance of common stock for conversion of convertible debt" } } }, "auth_ref": [] }, "crbp_IssuanceOfSeriesARedeemablePreferredStockShares": { "xbrltype": "sharesItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "IssuanceOfSeriesARedeemablePreferredStockShares", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity1" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Series A Redeemable Preferred Stock, shares", "label": "Issuance of Series A Redeemable Preferred Stock, shares", "documentation": "Issuance of Series A Redeemable Preferred Stock, shares" } } }, "auth_ref": [] }, "crbp_JanuaryOneTwoThousandTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "JanuaryOneTwoThousandTwentyFourMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "January One Two Thousand Twenty Four [Member]", "label": "January One Two Thousand Twenty Four [Member]", "terseLabel": "January 1, 2024 [Member]" } } }, "auth_ref": [] }, "crbp_JanuaryOneTwoThousandTwentyMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "JanuaryOneTwoThousandTwentyMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "January 1, 2020 [Member]", "documentation": "January 1, 2020 [Member]" } } }, "auth_ref": [] }, "crbp_JanuaryOneTwoThousandTwentyOneMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "JanuaryOneTwoThousandTwentyOneMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "January 1, 2021 [Member]", "documentation": "January 1, 2021 [Member].", "terseLabel": "January 1, 2021 [Member]" } } }, "auth_ref": [] }, "crbp_JanuaryOneTwoThousandTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "JanuaryOneTwoThousandTwentyThreeMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "January 1, 2023 [Member]", "label": "January 1, 2023 [Member]", "documentation": "January One Two Thousand Twenty Three [Member]" } } }, "auth_ref": [] }, "crbp_JanuaryOneTwoThousandTwentyTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "JanuaryOneTwoThousandTwentyTwoMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "January One Two Thousand Twenty Two [Member]", "label": "January One Two Thousand Twenty Two [Member]", "terseLabel": "January 1, 2022 [Member]" } } }, "auth_ref": [] }, "crbp_JefferiesLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "JefferiesLLCMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/LiquidityDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Jefferies LLC [Member]", "documentation": "Jefferies LLC [Member]", "terseLabel": "Jefferies LLC [Member]" } } }, "auth_ref": [] }, "crbp_JenrinAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "JenrinAgreementMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureLicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Jenrin Agreement [Member]", "documentation": "Jenrin Agreement [Member]", "terseLabel": "Jenrin Agreement [Member]" } } }, "auth_ref": [] }, "crbp_JuneThirtyTwoThousandTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "JuneThirtyTwoThousandTwentyFourMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureNotesPayableScheduleOfPrincipalMaturitiesOnLongTermDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "June thirty two thousand twenty four.", "label": "June Thirty Two Thousand Twenty Four [Member]", "terseLabel": "June 30, 2024" } } }, "auth_ref": [] }, "crbp_K2HealthventuresLlcDebtConversionMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "K2HealthventuresLlcDebtConversionMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "K2 HealthVentures LLC Debt Conversion [Member]", "label": "K2 HealthVentures LLC Debt Conversion [Member]" } } }, "auth_ref": [] }, "crbp_K2HvAmendedLoanAndSecurityAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "K2HvAmendedLoanAndSecurityAgreementMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "K2HV Amended Loan and Security Agreement [Member]", "label": "K2HV Amended Loan and Security Agreement [Member]" } } }, "auth_ref": [] }, "crbp_K2WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "K2WarrantMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfWeightedAverageAssumptionOfWarrantsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "K2 Warrant [Member]", "documentation": "K2 Warrant [Member]", "label": "K2 Warrant [Member] [Default Label]" } } }, "auth_ref": [] }, "crbp_KTwoHealthVenturesLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "KTwoHealthVenturesLLCMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DerivativeLiabilityDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "K2 HealthVentures LLC [Member]", "documentation": "K2 HealthVentures LLC [Member]", "terseLabel": "K2 HealthVentures LLC [Member]" } } }, "auth_ref": [] }, "crbp_KTwoWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "KTwoWarrantMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsTables" ], "lang": { "en-us": { "role": { "label": "K2 Warrant [Member]", "documentation": "K2 Warrant [Member]", "terseLabel": "K2 Warrant [Member]" } } }, "auth_ref": [] }, "crbp_KakenPharmaceuticalCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "KakenPharmaceuticalCoLtdMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Kaken Pharmaceutical Co., Ltd. [Member]", "documentation": "Kaken Pharmaceutical Co., Ltd. [Member]" } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Lease, Cost, Total", "label": "Lease, Cost" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "verboseLabel": "SCHEDULE OF LEASE COSTS", "terseLabel": "SCHEDULE OF LEASE COSTS" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsGross", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Leasehold Improvements, Gross", "terseLabel": "Leasehold improvements" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements [Member]" } } }, "auth_ref": [] }, "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdsAndLeaseholdImprovementsMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Leaseholds and Leasehold Improvements [Member]", "terseLabel": "Leaseholds and Leasehold Improvements [Member]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DerivativeLiabilityDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/LiquidityDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity:", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "crbp_LendersMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "LendersMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "Lenders [Member]", "label": "Lenders [Member]", "documentation": "Lenders [Member]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "2021", "terseLabel": "2024" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "2023", "terseLabel": "2026" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "2022", "terseLabel": "2025" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseOptionToExtend", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Option to Extend", "terseLabel": "Operating lease, option to extend" } } }, "auth_ref": [] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LetterOfCreditMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit [Member]" } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAssumed1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAssumed1", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Liabilities Assumed" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilityForUncertainTaxPositionsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForUncertainTaxPositionsCurrent", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Liability for Uncertainty in Income Taxes, Current", "terseLabel": "Uncertain tax position" } } }, "auth_ref": [] }, "crbp_LicenceIssuanceFee": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "LicenceIssuanceFee", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureLicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "License issuance fee", "documentation": "Licence issuance fee.", "terseLabel": "License issuance fee" } } }, "auth_ref": [] }, "crbp_LicenseAgreementsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "LicenseAgreementsTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureLicenseAgreement" ], "lang": { "en-us": { "role": { "label": "LICENSE AGREEMENTS", "documentation": "License Agreements [Text Block]", "terseLabel": "LICENSE AGREEMENT" } } }, "auth_ref": [] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCredit", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "totalLabel": "Long-term Line of Credit, Total", "label": "Long-Term Line of Credit", "terseLabel": "Irrevocable letter of credit" } } }, "auth_ref": [] }, "us-gaap_LitigationSettlementExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationSettlementExpense", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSubsequentEventsConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Litigation Settlement, Expense", "terseLabel": "Litigation settlement" } } }, "auth_ref": [] }, "crbp_LoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "LoanAgreementMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DerivativeLiabilityDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loan Agreement [Member]", "documentation": "Loan Agreement [Member]", "terseLabel": "Loan Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_LoansPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansPayable", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "totalLabel": "Loans Payable, Total", "label": "Loans Payable", "terseLabel": "Remainder payable upon the achievement of the last remaining milestone" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureNotesPayableScheduleOfPrincipalMaturitiesOnLongTermDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureNotesPayableScheduleOfPrincipalMaturitiesOnLongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt", "totalLabel": "Total" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureNotesPayableScheduleOfNotesPayableDetails2": { "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureNotesPayableScheduleOfNotesPayableDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: current portion of long-term debt", "terseLabel": "Less: current portion of long-term debt", "label": "Long-Term Debt, Current Maturities", "totalLabel": "Total long-term debt, net of discount" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureNotesPayableScheduleOfPrincipalMaturitiesOnLongTermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureNotesPayableScheduleOfPrincipalMaturitiesOnLongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year One", "verboseLabel": "Total Fiscal Year Ending 2024" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureNotesPayableScheduleOfPrincipalMaturitiesOnLongTermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureNotesPayableScheduleOfPrincipalMaturitiesOnLongTermDebtDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "Long-Term Debt, Maturity, Year Three" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureNotesPayableScheduleOfPrincipalMaturitiesOnLongTermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureNotesPayableScheduleOfPrincipalMaturitiesOnLongTermDebtDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2024", "label": "Long-Term Debt, Maturity, Year Two" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 }, "http://corbuspharma.com/20231231/taxonomy/role/DisclosureNotesPayableScheduleOfNotesPayableDetails2": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureNotesPayableScheduleOfNotesPayableDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt, net of debt discount", "totalLabel": "Total long-term debt, net of discount" } } }, "auth_ref": [] }, "stpr_MA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2023", "localname": "MA", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "MASSACHUSETTS", "terseLabel": "MASSACHUSETTS [Member]" } } }, "auth_ref": [] }, "crbp_MarchThirtyOneTwoThousandTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "MarchThirtyOneTwoThousandTwentyFourMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureNotesPayableScheduleOfPrincipalMaturitiesOnLongTermDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "March thirty one two thousand twenty four.", "label": "March Thirty One Two Thousand Twenty Four [Member]", "terseLabel": "March 31, 2024" } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "SUMMARY OF MARKETABLE SECURITIES", "label": "Marketable Securities [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations2": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSubsequentEventsConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Change in unrealized gain (loss) on marketable debt securities", "totalLabel": "Marketable Securities, Unrealized Gain (Loss), Total", "label": "Marketable Security, Unrealized Gain (Loss)" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureLicenseAgreementDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "auth_ref": [] }, "crbp_MayThirtyOneTwoThousendThirtyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "MayThirtyOneTwoThousendThirtyThreeMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/LiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "May Thirty One Two Thousend Thirty Three [Member]", "label": "May Thirty One Two Thousend Thirty Three [Member]" } } }, "auth_ref": [] }, "crbp_MayTwoThousandAndTwentyThreeSaleAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "MayTwoThousandAndTwentyThreeSaleAgreementMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "May two thousand and twenty three sale agreement.", "label": "May Two Thousand And Twenty Three Sale Agreement [Member]", "terseLabel": "May 2023 Sale Agreement [Member]" } } }, "auth_ref": [] }, "crbp_MayTwoThousandTwentyThreeSaleAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "MayTwoThousandTwentyThreeSaleAgreementMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/LiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "May two thousand twenty three Sale Agreement [member]", "label": "May two thousand twenty three Sale Agreement [member]", "terseLabel": "May 2023 Sale Agreement [Member]" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r45" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r45" ] }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfWeightedAverageAssumptionOfWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Dividend Rate [Member]" } } }, "auth_ref": [] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedTermMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfWeightedAverageAssumptionOfWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Term [Member]" } } }, "auth_ref": [] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfWeightedAverageAssumptionOfWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Price Volatility [Member]" } } }, "auth_ref": [] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfWeightedAverageAssumptionOfWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "auth_ref": [] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfWeightedAverageAssumptionOfWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]" } } }, "auth_ref": [] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfWeightedAverageAssumptionOfWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]" } } }, "auth_ref": [] }, "crbp_MilkyWayLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "MilkyWayLicenseAgreementMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureLicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Milky Way Licence Agreement [Member]", "documentation": "Milky Way Licence Agreement [Member]", "terseLabel": "Milky Way License Agreement Member" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureLicenseAgreementDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum [Member]", "label": "Minimum [Member]" } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r65" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds [Member]" } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r73" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r46" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NatureOfOperations", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NatureOfOperations" ], "lang": { "en-us": { "role": { "label": "Nature of Operations [Text Block]", "terseLabel": "NATURE OF OPERATIONS" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations2": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 0.0 }, "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfComponentsNetLossDetails", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfComputationOfNetLossPerCommonShareDetails", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSubsequentEventsConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity1", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "verboseLabel": "Net income (loss)", "totalLabel": "Net loss" } } }, "auth_ref": [] }, "crbp_NetOperatingLossCarryforwardsLimitationPercentageOnTaxableIncome": { "xbrltype": "percentItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "NetOperatingLossCarryforwardsLimitationPercentageOnTaxableIncome", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net operating loss carryforwards limitation percentage on taxable income", "documentation": "Net operating loss carryforwards limitation percentage on taxable income.", "terseLabel": "Net operating loss carryforwards limitation percentage on taxable income" } } }, "auth_ref": [] }, "crbp_NetPoceedsAfterDeductingUnderwritingDiscountsAndCommissions": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "NetPoceedsAfterDeductingUnderwritingDiscountsAndCommissions", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/LiquidityDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Net Poceeds after deducting Underwriting Discounts and Commissions", "label": "Net Poceeds after deducting Underwriting Discounts and Commissions", "terseLabel": "Net poceeds after deducting underwriting discounts and commissions" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfWeightedAverageAssumptionOfWarrantsDetails", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Recently Adopted Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "auth_ref": [] }, "crbp_NewPremisesMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "NewPremisesMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "New Premises [Member]", "documentation": "New Premises [Member]", "terseLabel": "New Premises [Member]" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r45" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r14", "r26", "r36", "r53", "r62" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r43" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r42" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r53" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r73" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r73" ] }, "crbp_NonVestedStockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "NonVestedStockOptionsMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfNonvestedStockOptionDetails" ], "lang": { "en-us": { "role": { "documentation": "Non-vested stock options [Member]", "label": "Non-vested stock options [Member]", "terseLabel": "Non-vested stock options" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSubsequentEventsConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Other income (expense), net", "label": "Nonoperating Income (Expense)" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense), net:" } } }, "auth_ref": [] }, "crbp_NotInDefaultOnFourthAnniversaryMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "NotInDefaultOnFourthAnniversaryMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Not In Default On Fourth Anniversary [Member]", "documentation": "Not in Default on Fourth Anniversary [Member]", "terseLabel": "Not In Default On Fourth Anniversary [Member]" } } }, "auth_ref": [] }, "crbp_NotInDefaultOnThirdAnniversaryMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "NotInDefaultOnThirdAnniversaryMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Not In Default On Third Anniversary [Member]", "documentation": "Not in Default on Third Anniversary [Member]", "terseLabel": "Not In Default On Third Anniversary [Member]" } } }, "auth_ref": [] }, "us-gaap_NotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayable", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "totalLabel": "Notes Payable, Total", "verboseLabel": "Notes payable", "label": "Notes Payable" } } }, "auth_ref": [] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayableCurrent", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "totalLabel": "Notes Payable, Current, Total", "label": "Notes Payable, Current", "terseLabel": "Notes payable" } } }, "auth_ref": [] }, "crbp_NumberOfWarrantsExercisableForCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "NumberOfWarrantsExercisableForCommonStock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of warrants exercisable for common stock", "documentation": "Number of warrants exercisable for common stock." } } }, "auth_ref": [] }, "crbp_OctoberTwoThousandNineteenLeaseAmendmentMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "OctoberTwoThousandNineteenLeaseAmendmentMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "October 2019 Lease Amendment [Member]", "documentation": "October Two Thousand Nineteen Lease Amendment [Member]", "terseLabel": "October 2019 Lease Amendment [Member]" } } }, "auth_ref": [] }, "crbp_OfficeFurnitureAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "OfficeFurnitureAndEquipmentMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Office Furniture and Equipment [Member]", "documentation": "Office Furniture and Equipment [Member]", "terseLabel": "Office Furniture and Equipment [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSubsequentEventsConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "terseLabel": "Total operating expenses" } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSubsequentEventsConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSubsequentEventsConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Operating loss", "label": "Operating Income (Loss)", "terseLabel": "Operating loss" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "verboseLabel": "Operating lease cost" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Expense", "terseLabel": "Lease expenses" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLeaseIncomeTableTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Lease Income [Table Text Block]", "terseLabel": "SUMMARY OF UNDISCOUNTED SUBLEASE CASH INFLOWS" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Operating Lease, Liability, Total", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liability" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities, current" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, noncurrent" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Operating lease, right of use asset", "terseLabel": "Operating lease right-of-use assets" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseCostsDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "verboseLabel": "Weighted average remaining lease term" } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "totalLabel": "Operating Loss Carryforwards, Total", "label": "Operating Loss Carryforwards", "verboseLabel": "Net operating loss carryforwards" } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsLineItems", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfComponentsNetLossDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Line Items]" } } }, "auth_ref": [] }, "crbp_OperatingLossCarryforwardsNoExpiration": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "OperatingLossCarryforwardsNoExpiration", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net operating loss carryforwards no expiration", "documentation": "Net operating loss carryforwards no expiration.", "terseLabel": "Net operating loss carryforwards no expiration" } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsTable", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfComponentsNetLossDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Table]" } } }, "auth_ref": [] }, "us-gaap_OptionIndexedToIssuersEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OptionIndexedToIssuersEquityLineItems", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfFairValueOfOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Option Indexed to Issuer's Equity [Line Items]" } } }, "auth_ref": [] }, "us-gaap_OptionIndexedToIssuersEquityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OptionIndexedToIssuersEquityTable", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfFairValueOfOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Option Indexed to Issuer's Equity [Table]" } } }, "auth_ref": [] }, "us-gaap_OptionIndexedToIssuersEquityTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OptionIndexedToIssuersEquityTypeAxis", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfFairValueOfOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Option Indexed to Issuer's Equity, Type [Axis]" } } }, "auth_ref": [] }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OptionIndexedToIssuersEquityTypeDomain", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfFairValueOfOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Option Indexed to Issuer's Equity, Type [Domain]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "terseLabel": "Accrued other" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "totalLabel": "Other Assets, Noncurrent, Total", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations2": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSubsequentEventsConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Total other comprehensive income (loss)" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSubsequentEventsConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity1" ], "lang": { "en-us": { "role": { "terseLabel": "Change in unrealized gain (loss) on marketable debt securities", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax" } } }, "auth_ref": [] }, "us-gaap_OtherIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncomeMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Other Income [Member]", "terseLabel": "Other Income [Member]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureLicenseAgreementDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "totalLabel": "Other Liabilities, Noncurrent, Total", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "auth_ref": [] }, "us-gaap_OtherLongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLongTermDebtCurrent", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Other Long-Term Debt, Current", "terseLabel": "Current portion of long-term debt" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSubsequentEventsConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Other Nonoperating Income (Expense), Total", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpenseAbstract", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSubsequentEventsConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense), net:" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r45" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r12", "r24", "r34", "r60" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r15", "r27", "r37", "r63" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r15", "r27", "r37", "r63" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r41" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentOfFinancingAndStockIssuanceCosts", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Payment of Financing and Stock Issuance Costs, Total", "negatedLabel": "Issuance costs paid for common stock financings", "label": "Payment of Financing and Stock Issuance Costs" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRoyalties", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Payments for Royalties" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/LiquidityDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquityParenthetical", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Payments of Stock Issuance Costs", "terseLabel": "Issuance costs incurred", "verboseLabel": "Issuance costs incurred, net proceeds" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Payments to Acquire Investments, Total", "label": "Payments to Acquire Investments", "negatedLabel": "Purchases of investments" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment" } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r44" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r44" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r43" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r53" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r46" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r42" ] }, "crbp_PercentageOfIncrementalBorrowingRateFromPresentValueOfLease": { "xbrltype": "percentItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "PercentageOfIncrementalBorrowingRateFromPresentValueOfLease", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Percentage of incremental borrowing rate from present value of lease", "documentation": "Percentage of incremental borrowing rate from present value of lease.", "terseLabel": "Percentage of incremental borrowing rate from present value of lease" } } }, "auth_ref": [] }, "crbp_PhaseTwoBClinicalTrialMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "PhaseTwoBClinicalTrialMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Phase 2b Clinical Trial [Member]", "documentation": "Phase 2b Clinical Trial [Member]" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]" } } }, "auth_ref": [] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]" } } }, "auth_ref": [] }, "crbp_PotentialMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "PotentialMilestonePayments", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureLicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Potential commercial milestone payments", "label": "Potential milestone payments", "documentation": "Potential milestone payments.", "terseLabel": "Potential milestone payments" } } }, "auth_ref": [] }, "us-gaap_PreferredStockLiquidationPreference": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockLiquidationPreference", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity1" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Liquidation Preference Per Share" } } }, "auth_ref": [] }, "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value", "label": "Preferred Stock, Par or Stated Value Per Share" } } }, "auth_ref": [] }, "us-gaap_PreferredStockRedemptionAmountFutureRedeemableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockRedemptionAmountFutureRedeemableSecurities", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity1" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Redemption Amount, Future Redeemable Securities" } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock authorised", "label": "Preferred Stock, Shares Authorized" } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred share, issued", "totalLabel": "Preferred Stock, Shares Issued, Total", "label": "Preferred Stock, Shares Issued" } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock outstanding", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "label": "Preferred Stock, Shares Outstanding" } } }, "auth_ref": [] }, "us-gaap_PreferredStockTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosurePreferredStock" ], "lang": { "en-us": { "role": { "terseLabel": "PREFERRED STOCK", "label": "Preferred Stock [Text Block]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance", "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance", "totalLabel": "Preferred Stock, Value, Issued, Total", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding at December 31, 2023 and December 31, 2022. See Note 12" } } }, "auth_ref": [] }, "us-gaap_PreferredUnitsDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredUnitsDescription", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Description", "label": "Preferred Units, Description" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "verboseLabel": "Prepaid Expense and Other Assets, Current", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid Expense, Current", "totalLabel": "Prepaid Expense, Current, Total", "label": "Prepaid Expense, Current" } } }, "auth_ref": [] }, "us-gaap_PrincipalAmountOutstandingOnLoansHeldForSaleOrSecuritization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrincipalAmountOutstandingOnLoansHeldForSaleOrSecuritization", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DerivativeLiabilityDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loan, Held-for-Sale or Securitization or Asset-Backed Financing Arrangement, Principal Outstanding", "terseLabel": "Outstanding Loan" } } }, "auth_ref": [] }, "crbp_ProbabilityOfDecreasedRepaymentOfLoan": { "xbrltype": "percentItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "ProbabilityOfDecreasedRepaymentOfLoan", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DerivativeLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Probability of decreased repayment of loan", "label": "Probability of decreased repayment of loan" } } }, "auth_ref": [] }, "crbp_ProbabilityOfIncreasedInRepaymentOfLoan": { "xbrltype": "percentItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "ProbabilityOfIncreasedInRepaymentOfLoan", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DerivativeLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Probability of increased in repayment of loan", "label": "Probability of increased in repayment of loan" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIncomeTaxRefunds": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIncomeTaxRefunds", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from Income Tax Refunds", "terseLabel": "Proceeds from Income Tax Refunds" } } }, "auth_ref": [] }, "crbp_ProceedsFromInvestmentsOnAchievingMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "ProceedsFromInvestmentsOnAchievingMilestones", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from investments on achieving milestones", "documentation": "Proceeds from investments on achieving milestones." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/LiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Proceeds from issuance initial public offering" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/LiquidityDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "verboseLabel": "Gross proceeds from sale of stock", "terseLabel": "Proceeds from issuance of common stock" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Proceeds from Issuance of Long-term Debt, Total", "label": "Proceeds from Issuance of Long-Term Debt", "terseLabel": "Proceeds from issuance of long-term borrowings", "verboseLabel": "Decrease in long-term debt" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfRedeemablePreferredStock", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity1" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption of Series A Redeemable Preferred Stock", "label": "Proceeds from Issuance of Redeemable Preferred Stock", "negatedLabel": "Redemption of Series A Redeemable Preferred Stock" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromNotesPayable", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Proceeds from Notes Payable, Total", "label": "Proceeds from Notes Payable", "terseLabel": "Proceeds from issuance of notes payable" } } }, "auth_ref": [] }, "crbp_ProceedsFromPrepaymentAndDefaultFeatures": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "ProceedsFromPrepaymentAndDefaultFeatures", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from prepayment and default features", "label": "Proceeds from prepayment and default features", "documentation": "Proceeds from prepayment and default features." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Proceeds from Sale, Maturity and Collection of Investments, Total", "label": "Proceeds from Sale, Maturity and Collection of Investments", "terseLabel": "Proceeds from sales and maturities of investments" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of property and equipment", "totalLabel": "Proceeds from Sale of Property, Plant, and Equipment, Total", "label": "Proceeds from Sale of Property, Plant, and Equipment" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from Warrant Exercises", "label": "Proceeds from Warrant Exercises" } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": [] }, "crbp_ProfessionalServicesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "ProfessionalServicesAgreementMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Professional Services Agreement [Member]", "documentation": "Professional Services Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSubsequentEventsConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/PropertyAndEquipment" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "PROPERTY AND EQUIPMENT" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/SummaryOfPropertyAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "totalLabel": "Property, Plant and Equipment, Gross, Total", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://corbuspharma.com/20231231/taxonomy/role/SummaryOfPropertyAndEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1", "http://corbuspharma.com/20231231/taxonomy/role/SummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "verboseLabel": "Property, Plant and Equipment, Net", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/PropertyAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "SUMMARY OF PROPERTY AND EQUIPMENT" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property and equipment, estimated useful life" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]", "verboseLabel": "Property, Plant and Equipment, Estimated Useful Lives" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r41" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r41" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureLicenseAgreementDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureLicenseAgreementDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [] }, "crbp_RealizedLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "RealizedLossOnInvestments", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Realized loss on investments", "label": "Realized loss on investments", "documentation": "Realized loss on investments" } } }, "auth_ref": [] }, "crbp_RecentlyIssuedAccountingPronouncementsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "RecentlyIssuedAccountingPronouncementsPolicyTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recently Issued Accounting Pronouncements", "documentation": "Recently Issued Accounting Pronouncements [Policy Text Block]" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r7", "r19", "r29", "r55" ] }, "us-gaap_RedeemablePreferredStockDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RedeemablePreferredStockDividends", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity1" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Series A Redeemable Preferred Stock", "label": "Redeemable Preferred Stock Dividends" } } }, "auth_ref": [] }, "crbp_RedemptionOfSeriesARedeemablePreferredStockShares": { "xbrltype": "sharesItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "RedemptionOfSeriesARedeemablePreferredStockShares", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity1" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption of Series A Redeemable Preferred Stock, shares", "label": "Redemption of Series A Redeemable Preferred Stock, shares", "documentation": "Redemption of Series A Redeemable Preferred Stock, shares" } } }, "auth_ref": [] }, "srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Domain]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfOtherLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfOtherLongTermDebt", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Repayments of Other Long-Term Debt", "negatedLabel": "Repayment of long-term borrowings" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfShortTermDebt", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Repayments of Short-term Debt, Total", "negatedLabel": "Repayment of short-term borrowings", "label": "Repayments of Short-Term Debt" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalize and amortize research and development, description", "label": "Research and Development Arrangement, Contract to Perform for Others, Description and Terms" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSubsequentEventsConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "totalLabel": "Research and Development Expense, Total", "label": "Research and Development Expense" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureLicenseAgreementDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsScheduleOfStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development Expense [Member]" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Expenses" } } }, "auth_ref": [] }, "crbp_ResearchAndDevelopmentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "ResearchAndDevelopmentPeriod", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Research and development period", "documentation": "Research and development period." } } }, "auth_ref": [] }, "crbp_ResearchAndExperimentalCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "ResearchAndExperimentalCosts", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfComponentsOfNetDeferredTaxAssetDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfComponentsOfNetDeferredTaxAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized research and development", "label": "Research and experimental costs", "documentation": "Research and experimental costs" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r8", "r20", "r30", "r56" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r9", "r21", "r31", "r57" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r16", "r28", "r38", "r64" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCash", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails", "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "totalLabel": "Restricted cash", "verboseLabel": "Restricted cash", "label": "Restricted Cash" } } }, "auth_ref": [] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashCurrent", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails": { "parentTag": "us-gaap_RestrictedCash", "weight": 1.0, "order": 0.0 }, "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails", "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "verboseLabel": "Restricted cash, current", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash" } } }, "auth_ref": [] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 }, "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails": { "parentTag": "us-gaap_RestrictedCash", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfCashAndCashEquivalentsDetails", "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash", "verboseLabel": "Restricted cash, noncurrent" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsScheduleOfStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/LiquidityDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "negatedLabel": "Retained earnings (accumulated deficit)", "label": "Retained Earnings (Accumulated Deficit)" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity1" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit [Member]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from awards", "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total", "verboseLabel": "Revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenue1" ], "lang": { "en-us": { "role": { "label": "DEVELOPMENT AWARDS AND DEFERRED REVENUE" } } }, "auth_ref": [] }, "crbp_RevenueToBeRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "RevenueToBeRecognized", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revenue to be recognized", "documentation": "Revenue to be recognized." } } }, "auth_ref": [] }, "crbp_ReverseStockSplitPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "ReverseStockSplitPolicyTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Reverse Stock Split Policy", "label": "Reverse Stock Split, Policy [Policy Text Block]", "documentation": "Reverse Stock Split [Policy Text Block]" } } }, "auth_ref": [] }, "crbp_RightOfUseAssetsObtainedInExchangeForLeaseObligationUponEntryIntoFebruary2019LeaseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "RightOfUseAssetsObtainedInExchangeForLeaseObligationUponEntryIntoFebruary2019LeaseAgreement", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Right of use assets obtained in exchange for lease obligation upon entry into lease agreements", "documentation": "Right of use assets obtained in exchange for lease obligation upon entry into February 2019 Lease Agreement.", "terseLabel": "Right of use assets obtained in exchange for lease obligation upon entry into lease agreements" } } }, "auth_ref": [] }, "crbp_RightOfUseAssetsObtainedInExchangeForLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "RightOfUseAssetsObtainedInExchangeForLeaseObligations", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Right of use assets obtained in exchange for lease obligation upon adoption of ASU 2016-02, net of deferred rent", "documentation": "Right of use assets obtained in exchange for lease obligation upon entry into February 2019 Lease Agreement.", "terseLabel": "Right of use assets obtained in exchange for lease obligation upon adoption of ASU 2016-02, net of deferred rent" } } }, "auth_ref": [] }, "crbp_RoyaltyPaymentPercentage": { "xbrltype": "percentItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "RoyaltyPaymentPercentage", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Royalty payment percentage", "documentation": "Royalty payment percentage." } } }, "auth_ref": [] }, "crbp_RoyaltyTermDescription": { "xbrltype": "stringItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "RoyaltyTermDescription", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Royalty term description", "documentation": "Royalty term description." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r73" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r73" ] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Sale of Stock, Consideration Received on Transaction" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/LiquidityDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Aggregate common stock sold, shares" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/LiquidityDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Price Per Share", "terseLabel": "Purchase price per share", "verboseLabel": "Sale of stock, price per share" } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/AccruedExpensesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "SCHEDULE OF ACCRUED EXPENSES" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "SCHEDULE OF CASH AND CASH EQUIVALENTS" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DerivativeLiabilityDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureLicenseAgreementDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/LiquidityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "auth_ref": [] }, "crbp_ScheduleOfComponentsOfNetLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "ScheduleOfComponentsOfNetLossTableTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Components Net Loss", "label": "Schedule Of Components Of Net Loss Table Text Block", "documentation": "Schedule Of Components Of Net Loss Table Text Block" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableTables" ], "lang": { "en-us": { "role": { "terseLabel": "SCHEDULE OF NOTES PAYABLE", "label": "Schedule of Debt [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "SCHEDULE OF COMPONENTS OF NET DEFERRED TAX ASSET" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DerivativeLiabilityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]", "terseLabel": "SCHEDULE OF FAIR VALUE OF DERIVATIVE LIABILITY" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "SCHEDULE OF COMPUTATION OF NET LOSS PER COMMON SHARE" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsScheduleOfStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAwardsTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON RECURRING BASIS" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSummaryOfInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Net Investment Income [Line Items]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSummaryOfInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Investment Income [Table]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableTables" ], "lang": { "en-us": { "role": { "terseLabel": "SCHEDULE OF PRINCIPAL MATURITIES ON LONG TERM DEBT", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAwardsTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Restricted Stock Units, Vested and Expected to Vest [Table Text Block]", "terseLabel": "Summary of RSU activity" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAwardsTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "SUMMARY OF OPTION ACTIVITY" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAwardsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "SUMMARY OF FAIR VALUE OF OPTIONS GRANTED" } } }, "auth_ref": [] }, "crbp_ScheduleOfWeightedAverageAssumptionOfWarrantsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "ScheduleOfWeightedAverageAssumptionOfWarrantsTableTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/WarrantsTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF WEIGHTED AVERAGE ASSUMPTION OF WARRANTS", "documentation": "Schedule of Weighted Average Assumption of Warrants [Table Text Block]", "terseLabel": "SCHEDULE OF WEIGHTED AVERAGE ASSUMPTION OF WARRANTS" } } }, "auth_ref": [] }, "us-gaap_SecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebt", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DerivativeLiabilityDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "totalLabel": "Secured Debt, Total", "label": "Secured Debt", "terseLabel": "Secured debt" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r3" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfComponentsNetLossDetails", "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Information" } } }, "auth_ref": [] }, "crbp_SeptemberThirtyTwoThousandTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "SeptemberThirtyTwoThousandTwentyFourMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureNotesPayableScheduleOfPrincipalMaturitiesOnLongTermDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "September Thirty Two Thousand Twenty Four [Member]", "label": "September Thirty Two Thousand Twenty Four [Member]", "terseLabel": "September 30, 2024" } } }, "auth_ref": [] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesAPreferredStockMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity1" ], "lang": { "en-us": { "role": { "terseLabel": "Series A Redeemable Preferred Stock [Member]", "label": "Series A Preferred Stock [Member]" } } }, "auth_ref": [] }, "crbp_SeventhYearMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "SeventhYearMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Seventh Year [Member]", "documentation": "Seventh Year [Member]", "terseLabel": "Seventh Year [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total", "verboseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfRsuActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfRsuActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfRsuActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfRsuActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfRsuActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance", "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfRsuActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance", "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Ending Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfFairValueOfOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfFairValueOfOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfFairValueOfOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk free interest rate" } } }, "auth_ref": [] }, "crbp_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate": { "xbrltype": "percentItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfFairValueOfOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Estimated Forfeiture Rate", "documentation": "Estimated forfeiture rate.", "terseLabel": "Estimated Forfeiture Rate" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfNonvestedStockOptionDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised", "verboseLabel": "Warrants to purchase shares of common stock, exercised" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations, Total", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations", "terseLabel": "Shares, Expired", "negatedLabel": "Shares, Expired" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for future grants" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Shares, Exercisable" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Average intrinsic value of options exercised" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price , Expired" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Shares, Forfeited or canceled", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfNonvestedStockOptionDetails", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfNonvestedStockOptionDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant-date fair value, options granted" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Average Intrinsic Value, Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Total fair value of options vested" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Shares, Outstanding, Beginning balance", "periodEndLabel": "Shares, Outstanding, Ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Period Increase (Decrease), Total", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)", "terseLabel": "Increase in number of shares of common stock available for issuance" } } }, "auth_ref": [] }, "crbp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear": { "xbrltype": "percentItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Increases in number of shares of common stock available for issuance, minimum percentage of outstanding common stock", "documentation": "Share based compensation arrangement by share based payment award options outstanding period increase minimum percentage in each year.", "terseLabel": "Increases in number of shares of common stock available for issuance, minimum percentage of outstanding common stock" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Exercise Price, Outstanding, Beginning balance", "periodEndLabel": "Weighted Average Exercise Price, Outstanding, Ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average Intrinsic Value, Vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Exercisable" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "periodEndLabel": "Aggregate Intrinsic Value, Vested and expected to vest" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares, Vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "periodEndLabel": "Shares, Vested and expected to vest" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Vested and expected to vest" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum", "terseLabel": "Percentage of outstanding common shares" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsDetailsNarrative", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price, Exercised", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price, Forfeited", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price, Granted", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DerivativeLiabilityDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche One [Member]", "terseLabel": "Share-based Payment Arrangement, Tranche One [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheThreeMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Tranche Three [Member]", "label": "Share-Based Payment Arrangement, Tranche Three [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Tranche Two [Member]", "label": "Share-Based Payment Arrangement, Tranche Two [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-based Compensation" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfFairValueOfOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "verboseLabel": "Option granted expected term", "terseLabel": "Expected term in years" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfNonvestedStockOptionDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares", "periodStartLabel": "Shares Non-vested , Beginning balance", "periodEndLabel": "Shares Outstanding, Ending balance" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfNonvestedStockOptionDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares", "negatedLabel": "Shares, Forfeited" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfNonvestedStockOptionDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Fair Value, Forfeited" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfNonvestedStockOptionDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "periodStartLabel": "Weighted Average Fair Value Non Vested, Beginning Balance", "periodEndLabel": "Weighted Average Fair Value Non Vested, Ending Balance" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Term in Years, Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Term in Years, Vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Term in Years, Vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfNonvestedStockOptionDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares", "negatedLabel": "Shares, Vested" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfNonvestedStockOptionDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Fair Value, Vested" } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity1" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance, shares", "periodEndLabel": "Ending balance, shares", "label": "Shares, Outstanding" } } }, "auth_ref": [] }, "crbp_ShortTermDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "ShortTermDepositsMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Short term Deposits [Member]", "documentation": "Short term Deposits [Member]", "terseLabel": "Short term Deposits [Member]" } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "totalLabel": "Short-term Investments, Total", "label": "Short-Term Investments", "terseLabel": "Investments" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES" } } }, "auth_ref": [] }, "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]" } } }, "auth_ref": [] }, "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table]" } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity1" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity1", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]" } } }, "auth_ref": [] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfComponentsNetLossDetails", "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSubsequentEventsConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity1" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSubsequentEventsConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfWeightedAverageAssumptionOfWarrantsDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity1", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r11", "r23", "r33", "r59" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureLicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Stock Issued During Period, Shares, Acquisitions" } } }, "auth_ref": [] }, "crbp_StockIssuedDuringPeriodSharesCommonStockUponExerciseOfWarrantsShares": { "xbrltype": "sharesItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "StockIssuedDuringPeriodSharesCommonStockUponExerciseOfWarrantsShares", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity1" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock upon exercise of warrants, shares", "documentation": "Stock issued during period shares common stock upon exercise of warrants.", "terseLabel": "Issuance of common stock upon exercise of warrants, shares" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/LiquidityDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity1" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock, net of issuance costs, shares", "verboseLabel": "Shares issued" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issued during period, shares, reverse stock splits", "label": "Stock Issued During Period, Shares, Reverse Stock Splits" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsSummaryOfOptionActivityDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity1", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Shares, Exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "terseLabel": "Issuance of common stock upon exercise of stock options, shares" } } }, "auth_ref": [] }, "crbp_StockIssuedDuringPeriodValueCommonStockUponExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "StockIssuedDuringPeriodValueCommonStockUponExerciseOfWarrants", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity1" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock upon exercise of warrants", "documentation": "Stock issued during period value common stock upon exercise of warrants.", "terseLabel": "Issuance of common stock upon exercise of warrants" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity1" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock, net of issuance costs" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity1" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of stock options" } } }, "auth_ref": [] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockOptionMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Option [Member]", "terseLabel": "Equity Option [Member]" } } }, "auth_ref": [] }, "crbp_StockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "StockOptionsMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsScheduleOfStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Stock Options [member]", "label": "Stock Options [member]" } } }, "auth_ref": [] }, "crbp_StockSubscriptionReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "StockSubscriptionReceivable", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock subscriptions receivable", "documentation": "Stock subscription receivable.", "label": "StockSubscriptionReceivable", "terseLabel": "Stock subscription receivable" } } }, "auth_ref": [] }, "crbp_StockSubscriptionsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "StockSubscriptionsReceivable", "crdr": "debit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Stock subscriptions receivable", "documentation": "Stock subscriptions receivable.", "terseLabel": "Stock Subscriptions Receivable" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity1" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning balance, value", "periodEndLabel": "Ending balance, value", "label": "Equity, Attributable to Parent" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommonStock" ], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "terseLabel": "COMMON STOCK" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityReverseStockSplit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders Equity, Reverse Stock Split", "label": "Stockholders' Equity, Reverse Stock Split" } } }, "auth_ref": [] }, "crbp_SubleaseAgreementDescription": { "xbrltype": "stringItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "SubleaseAgreementDescription", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sublease Agreement Description", "documentation": "Sublease agreement description.", "terseLabel": "Sublease Agreement Description" } } }, "auth_ref": [] }, "crbp_SubleaseArea": { "xbrltype": "areaItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "SubleaseArea", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sublease Area", "documentation": "Sublease Area", "terseLabel": "Sublease to third party" } } }, "auth_ref": [] }, "crbp_SubleaseAreaTotal": { "xbrltype": "areaItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "SubleaseAreaTotal", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sublease Area Total", "documentation": "Sublease area total.", "terseLabel": "Total sublease area" } } }, "auth_ref": [] }, "crbp_SubleasesIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "SubleasesIncome", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Subleases Income", "label": "Subleases Income", "terseLabel": "Sublease income" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSubsequentEventsConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://corbuspharma.com/20231231/taxonomy/role/LiquidityDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSubsequentEventsConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://corbuspharma.com/20231231/taxonomy/role/LiquidityDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSubsequentEventsConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://corbuspharma.com/20231231/taxonomy/role/LiquidityDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Liquidity" ], "lang": { "en-us": { "role": { "terseLabel": "LIQUIDITY", "label": "Substantial Doubt about Going Concern [Text Block]" } } }, "auth_ref": [] }, "crbp_SummaryOfNonvestedStockOptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "SummaryOfNonvestedStockOptionsTableTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockBasedCompensationAwardsTables" ], "lang": { "en-us": { "role": { "label": "SUMMARY OF NON-VESTED STOCK OPTIONS", "terseLabel": "SUMMARY OF NON-VESTED STOCK OPTIONS", "documentation": "Summary Of Nonvested Stock Options Table Text Block" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information and non cash transactions:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r52" ] }, "crbp_TermDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "TermDepositsMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSummaryOfInvestmentsDetails", "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Term Deposits [Member]", "documentation": "Term Deposits [Member]" } } }, "auth_ref": [] }, "crbp_ThirdAndFourthAnniversaryMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "ThirdAndFourthAnniversaryMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Third And Fourth Anniversary [Member]", "label": "Third And Fourth Anniversary [Member]" } } }, "auth_ref": [] }, "crbp_ThirdAnniversaryMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "ThirdAnniversaryMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Third Anniversary [Member]", "documentation": "Third Anniversary [Member]", "terseLabel": "Third Anniversary [Member]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "auth_ref": [] }, "crbp_TotalPremisesMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "TotalPremisesMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Total Premises [Member]", "documentation": "Total Premises [Member]", "terseLabel": "Total Premises [Member]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r44" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r51" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r72" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r74" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSummaryOfInvestmentsDetails", "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]" } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r75" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r76" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r74" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r74" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r77" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r75" ] }, "crbp_TwoThousandAndEighteenCffAwardMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "TwoThousandAndEighteenCffAwardMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "2018 CFF Award [Member]", "documentation": "2018 CFF Award [Member]", "label": "2018 CFF Award [Member] [Default Label]" } } }, "auth_ref": [] }, "crbp_TwoThousandFourteenEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "TwoThousandFourteenEquityIncentivePlanMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAwardsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2014 Equity Incentive Plan [Member]", "documentation": "2014 Equity Incentive Plan [Member]", "terseLabel": "2014 Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_TypeOfAdoptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfAdoptionMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Domain]" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DerivativeLiabilityDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureLicenseAgreementDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/LiquidityDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "auth_ref": [] }, "crbp_UCSFLincenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "UCSFLincenseAgreementMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureLicenseAgreementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "UCSF Lincense Agreement [Member]", "documentation": "UCSF Lincense Agreement [Member]", "terseLabel": "UCSF Lincense Agreement [Member]" } } }, "auth_ref": [] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureScheduleOfComponentsNetLossDetails" ], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "auth_ref": [] }, "crbp_UnderwritersMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "UnderwritersMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Underwriters [Member]", "documentation": "Underwriters [Member]", "terseLabel": "Underwriters [Member]" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r71" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance", "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance", "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized Tax Benefits" } } }, "auth_ref": [] }, "us-gaap_UnsecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnsecuredDebt", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "totalLabel": "Unsecured Debt, Total", "label": "Unsecured Debt", "terseLabel": "Unsecured letter of credit" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "auth_ref": [] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "Deferred tax assets valuation allowance increase" } } }, "auth_ref": [] }, "crbp_ValueOfCommonStockToBeSold": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "ValueOfCommonStockToBeSold", "crdr": "credit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Value of common stock to be sold", "documentation": "Value of common stock to be sold.", "terseLabel": "Value of common stock to be sold" } } }, "auth_ref": [] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingAxis", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DerivativeLiabilityDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Vesting [Axis]" } } }, "auth_ref": [] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingDomain", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DerivativeLiabilityDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/NotesPayableDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Vesting [Domain]" } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/CommonStockDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerCommonShareDetails", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "terseLabel": "Warrant [Member]" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingMaturityDate", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Maturity Date", "verboseLabel": "Warrant expire date" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfWeightedAverageAssumptionOfWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Measurement Input" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfWeightedAverageAssumptionOfWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Term" } } }, "auth_ref": [] }, "crbp_WarrantsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "WarrantsDisclosureTextBlock", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/Warrants" ], "lang": { "en-us": { "role": { "label": "WARRANTS", "documentation": "Warrants Disclosure [Text Block]", "terseLabel": "WARRANTS" } } }, "auth_ref": [] }, "crbp_WarrantsExercisableOnCompletionOfFinalMilestoneMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "WarrantsExercisableOnCompletionOfFinalMilestoneMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureDevelopmentAwardsAndDeferredRevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants Exercisable On Completion Of Final Milestone [Member]", "documentation": "Warrants Exercisable On Completion Of Final Milestone [Member]" } } }, "auth_ref": [] }, "crbp_WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "WarrantsMember", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/ScheduleOfWeightedAverageAssumptionOfWarrantsDetails", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative", "http://corbuspharma.com/20231231/taxonomy/role/WarrantsTables" ], "lang": { "en-us": { "role": { "label": "Warrants [Member]", "documentation": "Warrants [Member]", "terseLabel": "Warrants [Member]" } } }, "auth_ref": [] }, "crbp_WarrantsWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "WarrantsWeightedAverageRemainingContractualTerm", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/WarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining life of warrants", "documentation": "Warrants weighted average remaining contractual term." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSubsequentEventsConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of common shares outstanding, diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfComputationOfNetLossPerCommonShareDetails", "http://corbuspharma.com/20231231/taxonomy/role/DisclosureSubsequentEventsConsolidatedStatementsOfOperationsAndComprehensiveLossDetails", "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average number of common shares outstanding, basic", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average number of common shares-basic" } } }, "auth_ref": [] }, "crbp_WriteOffOfFullyDepreciatedPropertyAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://corbuspharma.com/20231231", "localname": "WriteOffOfFullyDepreciatedPropertyAndEquipment", "crdr": "debit", "presentation": [ "http://corbuspharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Write off of fully depreciated property and equipment", "documentation": "Write off of fully depreciated property and equipment", "terseLabel": "Write-off of fully depreciated property and equipment" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r20": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r21": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r22": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r23": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r24": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r25": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r26": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r27": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r28": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r29": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r30": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r31": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r32": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r33": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r34": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r35": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r36": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r37": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r38": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r39": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r40": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r41": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r42": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r43": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r44": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r45": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r46": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r47": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r48": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r49": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r50": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r51": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r52": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r53": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r54": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r55": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r56": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r57": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r58": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r59": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r60": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r61": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r62": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r63": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r64": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r65": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r66": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r67": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r68": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r69": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r70": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r71": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r72": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r73": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r74": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r75": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r76": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r77": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r78": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r79": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r80": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" } } } ZIP 15 0000950170-24-034266-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-034266-xbrl.zip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crbp-20231231_htm.xml IDEA: XBRL DOCUMENT 0001595097 2024-03-08 0001595097 2023-01-01 2023-12-31 0001595097 2023-06-30 shares iso4217:USD true 0001595097 --12-31 FY 10-K/A true 2023-12-31 2023 false 001-37348 Corbus Pharmaceuticals Holdings, Inc. DE 46-4348039 500 River Ridge Drive Norwood MA 02062 617 963-0100 Common Stock, par value $0.0001 per share CRBP NASDAQ No No Yes Yes Non-accelerated Filer true false false false false 34571068 10493108 <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p> Corbus Pharmaceuticals Holdings, Inc. (the “Company”) is filing this Amendment No. 1 (this “Amendment No. 1”) to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Original Form 10-K”), filed with the Securities and Exchange Commission (the “SEC”) on March 12, 2024, only for the purpose of amending and restating Item 11 of Part III of the Original Form 10-K to include certain information which was inadvertently omitted in the Original Form 10-K.In addition, pursuant to SEC rules, Item 15 of Part IV of the Original Form 10-K is hereby amended solely to include, as Exhibits 31.1 and 31.2, new certifications of our principal executive officer and principal financial officer pursuant to Rule 13a-14(a) under the Exchange Act of 1934 (the “Exchange Act”). Because no financial statements are included in this Amendment No. 1 and this Amendment No. 1 does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4, and 5 of such certifications have been omitted. We are not including new certifications required by Rule 13a-14(b) under the Exchange Act as no financial statements are included in this Amendment No. 1.Except for the changes to Item 11 of Part III and the filing of related certifications added to the list of Exhibits in Item 15 of Part IV, this Amendment No. 1 makes no changes to the Original Form 10-K.In addition, no other information has been updated for any subsequent events occurring after March 12, 2024, the date of the filing of the Original Form 10-K. Accordingly, this Amendment No. 1 should be read in conjunction with the Original Form 10-K and our other filings made with the SEC subsequent to the filing of the Original Form 10-K. Unless the context otherwise requires, references in this Amendment No. 1 to “Corbus,” the “Company,” “we,” “us,” or “our” mean Corbus Pharmaceuticals Holdings, Inc. and its subsidiaries unless we state otherwise, or the context otherwise indicates. EisnerAmper LLP 274 Iselin, New Jersey